{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.14768"}, {"@name": "filename", "#text": "21140_310505.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "C\u00c9SAR LAZZAROTTO \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n EFETIVIDADE DA PROTE\u00cdNA C REATIVA E DA \n\nPROCALCITONINA NO DIAGN\u00d3STICO DE INFEC\u00c7\u00c3O E NA \n\nPREDI\u00c7\u00c3O DE MORTALIDADE EM PACIENTES COM \n\nCIRROSE HEP\u00c1TICA DESCOMPENSADA  \n \n\n \n\nDisserta\u00e7\u00e3o apresentada ao Programa do \n\nMestrado Profissional associado \u00e0 \n\nResid\u00eancia M\u00e9dica, da Universidade \n\nFederal de Santa Catarina, para obten\u00e7\u00e3o do \n\nt\u00edtulo de Mestre em Ci\u00eancias M\u00e9dicas. \n\n \n\n \n\n \n\nOrientadora: Prof.\u00aa Esther Buzaglo Dantas-\n\nCorr\u00eaa, Dr\na \n\n \n\n \n\n \n\n \n\n \n\n \n\nFLORIAN\u00d3POLIS, SC \n\n2012\n\n\n\n\n\n \n\n \n\n \n\n \n\n \n\n\n\n\n\n \n\n \n\n \n\n \n\nC\u00c9SAR LAZZAROTTO \n\n \n\nEFETIVIDADE DA PROTE\u00cdNA C REATIVA E DA \n\nPROCALCITONINA NO DIAGN\u00d3STICO DE INFEC\u00c7\u00c3O E NA \n\nPREDI\u00c7\u00c3O DE MORTALIDADE EM PACIENTES COM \n\nCIRROSE HEP\u00c1TICA DESCOMPENSADA  \nEsta disserta\u00e7\u00e3o foi julgada adequada para obten\u00e7\u00e3o do t\u00edtulo de \n\nmestre em Ci\u00eancia M\u00e9dicas - \u00c1rea de Concentra\u00e7\u00e3o em Cuidados \n\nIntensivos e Paliativos - e aprovada em sua forma pelo Programa do \n\nMestrado Profissional associado \u00e0 Resid\u00eancia M\u00e9dica, da Universidade \n\nFederal de Santa Catarina. \n\n \n\nFlorian\u00f3polis, 30 de maio de 2012 \n\n \n\n__________________________________________ \n\nProf.\u00aa Dr.\u00aa Raquel Duarte Moritz \n\nCoordenadora do Programa do Mestrado Profissional \n\nBANCA EXAMINADORA \n\n \n\n_____________________________________ \n\nProf.\u00aa Dr.\u00aa Esther Buzaglo Dantas-Corr\u00eaa \n\nPresidente \n\n \n\n \n\n______________________________________ \n\nProf. Dr. Leonardo de Lucca Schiavon \n\nMembro \n\n \n\n \n\n______________________________________ \n\nProf.\na\n Dr.\n\na\n Jana\u00edna Luz Narciso Schiavon \n\nMembro \n\n \n\n______________________________________ \n\nProf. Dr. Ylmar Corr\u00eaa Neto  \n\nMembro \n\n\n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\nDear Doctor C\u00e9sar Lazzarotto \n\n \n\n \n\nThank you for sending your manuscript to the Journal of \n\nGastrointestinal and Liver Diseases for publication. \n\n \n\nYour submission has been assigned the following manuscript \n\nnumber: 1296/2012-09-14 \n\n \n\nYou may check on the progress of its evaluation by logging on \n\nto our website and using your user name and password. \n\n \n\nThank you for submitting your work to this journal. \n\n \n\nBest regards, \n\n \n\nMonica Acalovschi \n\n \n\nEditor-in-chief \n\n \n\nJournal of Gastrointestinal and Liver Diseases \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\nAGRADECIMENTOS \n\n \n\nAgrade\u00e7o a Deus pela prote\u00e7\u00e3o, permitindo a concretiza\u00e7\u00e3o \ndeste trabalho. \n\nAos meus pais, Itamar e Maria Aparecida Lazzarotto, pelo apoio \n\nem toda a minha vida, e por terem incentivado a minha forma\u00e7\u00e3o \nprofissional.  \n\nAos meus irm\u00e3os, M\u00f4nica e Andr\u00e9, pelo apoio e conviv\u00eancia \ndurante os anos da minha forma\u00e7\u00e3o profissional. \n\n\u00c0 Carla, minha namorada e companheira, pelo amor, ajuda e \n\npaci\u00eancia durante toda a resid\u00eancia m\u00e9dica.  \n\u00c0 minha orientadora Prof\u00aa. Dra Esther Buzaglo Dantas-Corr\u00eaa, \n\nobrigado pelos ensinamentos e pelo incentivo durante a minha \n\nforma\u00e7\u00e3o em gastroenterologia. \nAos professores Dr\u00aa. Jana\u00edna Luz Narciso Schiavon, e em \n\nespecial, ao Dr. Leonardo de Lucca Schiavon, pelo aprendizado, \nconhecimentos repassados, dedica\u00e7\u00e3o profissional e pelo aux\u00edlio \n\nprestado durante todas as etapas deste trabalho. \n\nAos amigos Dr. Leonardo Fayad e Dr. Marcelo Fernando \n\nRonsoni, pela parceria e companheirismo durante a coleta dos dados do \n\ntrabalho. \n\nAos amigos e colegas de Mestrado, Renata Cristina Viana, \nLeonardo Jonck Staub e Eduardo Jardim Berbigier, pela amizade, e \n\naprendizado durante os dois anos de resid\u00eancia e mestrado.  \nA todos os meus amigos, pelo apoio e pelos momentos de \n\ndescontra\u00e7\u00e3o e alegria. \n\nAos professores do Programa do Mestrado Profissional ligado \u00e0 \nResid\u00eancia M\u00e9dica, por terem contribu\u00eddo na minha forma\u00e7\u00e3o \n\nprofissional. \nAos profissionais do laborat\u00f3rio de an\u00e1lises cl\u00ednicas e de \n\npesquisa do Hospital Universit\u00e1rio \u2013 HU/UFSC, em especial \u00e0 \n\nfarmac\u00eautica Cristiane Nogueira, pela grande ajuda durante a coleta de \ndados. \n\nAos profissionais do laborat\u00f3rio central Santa Luzia, \n\nprincipalmente ao colega Nilton Cezar Zunino, pela import\u00e2ncia do \nservi\u00e7o prestado durante a an\u00e1lise bioqu\u00edmica da disserta\u00e7\u00e3o. \n\n\n\n \n\n \n\n  A todos que, de alguma forma, contribu\u00edram para a \nconcretiza\u00e7\u00e3o deste trabalho. \n\nEm especial, aos pacientes volunt\u00e1rios e familiares, pois sem as \nsuas colabora\u00e7\u00f5es, jamais se realizaria a presente disserta\u00e7\u00e3o. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nRESUMO \n\n \n\nIntrodu\u00e7\u00e3o: Infec\u00e7\u00e3o bacteriana \u00e9 uma complica\u00e7\u00e3o frequente nos \n\npacientes com cirrose hep\u00e1tica descompensada, proporcionando um \n\nimpacto negativo durante o acompanhamento desses indiv\u00edduos. \n\nObjetivos: Avaliar a efetividade da prote\u00edna C reativa (PCR) e da \n\nprocalcitonina (PCT) no diagn\u00f3stico de infec\u00e7\u00e3o e investigar a rela\u00e7\u00e3o \n\nentre esses biomarcadores inflamat\u00f3rios com a mortalidade ap\u00f3s a \n\nadmiss\u00e3o hospitalar. M\u00e9todo: Estudo prospectivo que incluiu pacientes \n\ncom cirrose hep\u00e1tica descompensada que foram submetidos \u00e0 \n\ninvestiga\u00e7\u00e3o de infec\u00e7\u00e3o e realiza\u00e7\u00e3o de dosagens s\u00e9ricas de PCR e PCT \n\nna admiss\u00e3o hospitalar. Resultados: Um total de 64 pacientes e 81 \n\ninterna\u00e7\u00f5es hospitalares foram inclu\u00eddas no estudo. A m\u00e9dia de idade foi \n\n54,31\u00b111,87 anos com predom\u00ednio do sexo masculino (68,8%). \n\nConcentra\u00e7\u00f5es s\u00e9ricas da PCR e da PCT estavam significativamente \n\nmais elevadas nos pacientes infectados (PCR mediana: 81,55 vs. 6,78; p \n&lt;0,001 e PCT mediana: 2,50 vs. 0,19; p &lt;0,001). \u00c1reas sob a curva \n\nROC da PCR e da PCT para o diagn\u00f3stico de infec\u00e7\u00e3o foram, \n\nrespectivamente 0,835 \u00b1 0,052 e 0,86 \u00b1 0,047. Pacientes que morreram \n\nat\u00e9 o 3\u00ba m\u00eas ap\u00f3s a admiss\u00e3o hospitalar apresentaram medianas da PCR \n\ne da PCT mais elevadas do que os sobreviventes (PCR 7,04 vs. 41,05 p \n\n= 0,026 e PCT 0,16 vs. 0,94 p = 0,001). Conclus\u00e3o: PCR e PCT foram \nconfi\u00e1veis marcadores de infec\u00e7\u00e3o bacteriana nos pacientes com cirrose \n\nhep\u00e1tica descompensada. Valores mais elevados de medianas da PCR e \n\nPCT foram encontrados nos pacientes que morreram, embora n\u00e3o houve \n\nassocia\u00e7\u00e3o entre infec\u00e7\u00e3o na admiss\u00e3o hospitalar e mortalidade no \n\nacompanhamento de sete dias e tr\u00eas meses. \n\nPalavras-chave: cirrose hep\u00e1tica, infec\u00e7\u00e3o bacteriana, prote\u00ednas \n\nde fase aguda. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\nABSTRACT \n \n\nIntroduction: Bacterial infection is a frequent complication in patients \n\nwith decompensated liver cirrhosis, providing negative impact during \n\nfollow-up of these individuals. Objective: To evaluate the effectiveness \n\nof C-reactive protein (CRP) and procalcitonin (PCT) in diagnosis of \n\ninfection and to investigate the relationship between these inflammatory \n\nbiomarkers with mortality after hospital admission. Methods: \n\nProspective study that included consecutive patients with \n\ndecompensated liver cirrhosis who underwent investigation for infection \n\nand achievement of serum CRP and PCT at hospital admission. Results: \n\nA total of 64 patients and 81 hospitalizations were included in the study. \n\nThe mean age was 54.31 \u00b1 11.87 years with male predominance \n\n(68.8%). Serum concentrations of CRP and PCT were significantly \n\nhigher in patients infected (CRP median: 81.55 vs 6.78, p&lt;0.001 and \n\nPCT median: 2.50 vs 0.19, p&lt;0.001). Areas under ROC curve of CRP \n\nand PCT for the diagnosis of infection were respectively 0.835 \u00b1 0.052 \n\nand 0.86 \u00b1 0.047. Patients who died until the third month after \n\nadmission showed medians of CRP and PCT higher than survivors \n\n(PCR 7.04 vs 41.05 p = 0.026 and PCT 0.16 vs 0.94 p = 0.001).  \n\nConclusion: CRP and PCT were reliable markers of infection in \n\npatients with decompensated liver cirrhosis. Higher values of medians \n\nof CRP and PCT were found in patients who died, although there was \n\nno association between infection at hospital admission and mortality in \n\nseven days and three months. \n\n \n\nKey words: liver cirrhosis, bacterial infections, acute-phase \n\nproteins  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\nLISTA DE FIGURAS \n\n \n\nFigura 1 - Curvas ROC da prote\u00edna C reativa e da procalcitonina \n\npara o diagn\u00f3stico de infec\u00e7\u00e3o na admiss\u00e3o hospitalar ....................   \n \n\n33 \n\n \n\n  \n\n\n\n\n\n \n\n \n\n \n\n \n\n\n\n\n\n \n\n \n\n \n\n \n\nLISTA DE TABELAS \n \n\nTabela 1 \n\nCaracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos \n\npacientes internados com cirrose hep\u00e1tica \n\ndescompensada  ....................................................... \n\n \n\n \n\n2\n\n28 \n\n1 \n\nTabela 2 \n\nFocos de infec\u00e7\u00e3o observados nos pacientes com \n\ncirrose hep\u00e1tica descompensada que foram \n\nadmitidos na unidade de emerg\u00eancia hospitalar ...... \n\n \n2 \n\nS\n\n29 \n\n1 \n\nTabela 3 \n\nMicroorganismos isolados em 81 admiss\u00f5es \n\nhospitalares de pacientes com cirrose hep\u00e1tica \n\ndescompensada \n\n................................................................................. \n\n \n\n3 \n\n \n\n30 \n\nTabela 4 \n\nVari\u00e1veis cl\u00ednicas e laboratoriais associadas \u00e0 \n\ninfec\u00e7\u00e3o na admiss\u00e3o \n\n................................................................................. \n\n3 \n\n3\n\n31 \n\nTabela 5 \n\nEfetividade dos pontos de corte da prote\u00edna C \n\nreativa e da procalcitonina no diagn\u00f3stico de \n\ninfec\u00e7\u00e3o durante a admiss\u00e3o hospitalar ................... \n\n \n\nf\n\n34 \n\nTabela 6 \n\nRela\u00e7\u00e3o da prote\u00edna C reativa e da procalcitonina \n\ncom o \u00f3bito no s\u00e9timo dia e no terceiro m\u00eas ap\u00f3s a \n\nadmiss\u00e3o hospitalar ................................................ \n\n \n\n3\n\n35 \n\n \n\n  \n\n\n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nLISTA DE ABREVIATURAS E SIGLAS \n\n \n\nACCP/SCCM \n\n \nAmerican College of Chest Physicians/Society of \n\nCritical Care Medicine \n\nCol\u00e9gio Americano de Pneumologistas/ \n\nSociedade M\u00e9dica de Cuidados Intensivos \n\nCDC \nCenter for Diseases Control \n\nCentro de Controle de Doen\u00e7as \n\nCEPSH Comit\u00ea de \u00c9tica em Pesquisa com Seres \n\nHumanos \n\nHDA Hemorragia digestiva alta \n\nHU Hospital Universit\u00e1rio \n\nIL-6 Interleucina-6 \n\nMELD \nModel for End-Stage Liver Disease \n\nModelo para Doen\u00e7a Hep\u00e1tica em Est\u00e1gio Final \n\nPBE Peritonite bacteriana espont\u00e2nea \n\nPCR Prote\u00edna C Reativa \n\nPCT Procalcitonina \n\nRNI Rela\u00e7\u00e3o normatizada internacional \n\nSIRS Systemic inflamatory response syndrome \nS\u00edndrome da resposta inflamat\u00f3ria sist\u00eamica \n\nTNF? Tumor necrosis factor-alpha \n\nFator de necrose tumoral alfa \n\nTCLE Termo de consentimento livre e esclarecido \n\nUFC Unidades formadoras de col\u00f4nias \n\nUFSC Universidade Federal de Santa Catarina \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n \n\n \n\nSUM\u00c1RIO \n\n \n\n \n\n1. INTRODU\u00c7\u00c3O ......................................................... 21 \n\n2. M\u00c9TODOS ............................................................... 23 \n\n2.1 DELINEAMENTO DO ESTUDO ................................. 23 \n\n2.2 SUJEITOS ................................................................. 23 \n\n2.3 INSTRUMENTOS E T\u00c9CNICAS DE COLETA  \n\n DE DADOS .............................................................. \n\n \n\n23 \n\n2.4 DETERMINA\u00c7\u00c3O DOS N\u00cdVEIS DA PROTE\u00cdNA \n\nC REATIVA E DA PROCALCITONINA ...................... \n\n \n\n24 \n\n2.5 AN\u00c1LISE ESTAT\u00cdSTICA ........................................... 25 \n\n3. RESULTADOS ........................................................... 27 \n\n3.1 CARACTER\u00cdSTICAS DA CASU\u00cdSTICA ...................... 27 \n\n3.2 FATORES ASSOCIADOS \u00c0 PRESEN\u00c7A DE \n\nINFEC\u00c7\u00c3O NA ADMISS\u00c3O HOSPITALAR ................ \n\n \n\n27 \n\n3.3 EFETIVIDADE DA PROTE\u00cdNA C REATIVA E  \n\nDA PROCALCITONINA NO DIAGN\u00d3STICO  \n\nDE INFEC\u00c7\u00c3O NA ADMISS\u00c3O HOSPITALAR .......... \n\n \n\n \n\n32 \n\n3.4 ASSOCIA\u00c7\u00c3O ENTRE A PROTE\u00cdNA C REATIVA E \n\nA PROCALCITONINA COM A MORTALIDADE  \n\nEM SETE DIAS E TR\u00caS MESES AP\u00d3S A  \n\nADMISS\u00c3O HOSPITALAR ........................................ \n\n \n\n \n\n \n\n32 \n\n4. DISCUSS\u00c3O ............................................................. 37 \n REFER\u00caNCIAS ........................................................ 43 \n ANEXOS ........................................................................... 49 \n ANEXO A - Certificado de aprova\u00e7\u00e3o do Comit\u00ea de \n\n\u00c9tica em Pesquisa com Seres Humanos (CEPSH) ............ \n\n \n\n49 \n\n ANEXO B - Crit\u00e9rios diagn\u00f3sticos de infec\u00e7\u00e3o conforme \n\no \u201cCenter for Diseases Control\u201d  ....................................... \n\n \n\n51 \n\n ANEXO C - Conceitos e defini\u00e7\u00f5es da \u201cAmerican \n\nCollege of Chest Physicians/Society of Critical Care \n\nMedicine\u201d \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... \n\n \n\n \n\n53 \n\n ANEXO D \u2013 Gradua\u00e7\u00e3o da encefalopatia hep\u00e1tica \n\nconforme os crit\u00e9rios de West-Haven ................................ \n\n \n\n55 \n\n ANEXO E \u2013 Classifica\u00e7\u00e3o de Child-Pugh ......................... 57 \n\n ANEXO F \u2013 F\u00f3rmula matem\u00e1tica para o c\u00e1lculo do \n\nmodelo MELD (Model for End-Stage Liver Disease) ....... \n \n\n59 \n\n AP\u00caNDICES ............................................................. 61 \n\n\n\n \n\n \n\n AP\u00caNDICE A - Termo de Consentimento Livre e \n\nEsclarecido (TCLE) ........................................................... \n\n \n\n61 \n\n AP\u00caNDICE B - Question\u00e1rio de avalia\u00e7\u00e3o dos  \n\ncirr\u00f3ticos descompensados na admiss\u00e3o hospitalar ........... \n\n \n\n65 \n\n AP\u00caNDICE C - Artigo Cient\u00edfico (Vers\u00e3o L\u00edngua \n\nInglesa) ............................................................................... \n\n \n\n71 \n\n \n\n\n\n\n\n21 \n\n \n\n \n\n \n\n1. INTRODU\u00c7\u00c3O \n \n\nA cirrose \u00e9 considerada o est\u00e1gio final da doen\u00e7a hep\u00e1tica \n\ncr\u00f4nica,\n1\n podendo ser desencadeada por diversas etiologias, como o \n\netilismo, as hepatites cr\u00f4nicas virais e autoimunes, al\u00e9m das desordens \n\nmetab\u00f3licas, vasculares ou biliares.\n2\n A hist\u00f3ria natural da cirrose \u00e9 \n\ncaracterizada por uma fase assintom\u00e1tica, denominada compensada, \n\nnormalmente sucedida por um estadio avan\u00e7ado que, por sua vez \u00e9 \n\nrepresentado pelo surgimento das complica\u00e7\u00f5es da cirrose. Esta fase, \n\nconhecida como descompensada, est\u00e1 associada a um progn\u00f3stico ruim, \n\ncom sobrevida mediana de aproximadamente dois anos.\n3\n  \n\nAs infec\u00e7\u00f5es bacterianas s\u00e3o frequentes nos pacientes portadores \n\nde cirrose hep\u00e1tica, principalmente na fase descompensada.\n4\n Esta \n\ncomplica\u00e7\u00e3o quadruplica o risco de mortalidade, sendo que 30% desses \n\npacientes que adquirem infec\u00e7\u00e3o bacteriana morrem dentro de um m\u00eas.\n5\n \n\nA maior preval\u00eancia de infec\u00e7\u00e3o entre os pacientes com grau avan\u00e7ado \n\nde disfun\u00e7\u00e3o hep\u00e1tica tem como fator contribuinte a presen\u00e7a de \n\nanormalidades no sistema imune associado ao aumento da transloca\u00e7\u00e3o \n\nbacteriana.\n6\n Al\u00e9m da defici\u00eancia da capacidade fagoc\u00edtica, a diminui\u00e7\u00e3o \n\nda atividade de opsoniza\u00e7\u00e3o tamb\u00e9m tem sido postulada como \n\nmediadora desta disfun\u00e7\u00e3o imune\n7\n. A combina\u00e7\u00e3o da redu\u00e7\u00e3o da s\u00edntese \n\nhep\u00e1tica e o aumento do consumo de complemento provocado por sua \n\nativa\u00e7\u00e3o exacerbada s\u00e3o prov\u00e1veis causas do preju\u00edzo da opsoniza\u00e7\u00e3o.\n8\n \n\nEsta ativa\u00e7\u00e3o parece ser provocada pelo aumento de endotoxinas \n\nprovenientes do intestino.\n9\n  \n\nO diagn\u00f3stico de infec\u00e7\u00e3o nos portadores de hepatopatias \n\ncr\u00f4nicas proporciona um impacto negativo consider\u00e1vel durante a \n\ninterna\u00e7\u00e3o hospitalar, j\u00e1 que \u00e9 a respons\u00e1vel por aproximadamente 30% \n\ndas mortes neste grupo de pacientes.\n10 \n\nOs achados cl\u00ednicos e \n\nlaboratoriais usuais de infec\u00e7\u00e3o, como a febre e a leucocitose podem \n\nestar ausentes.\n11\n\n Al\u00e9m disso, as culturas bacterianas necessitam 24 a 48 \n\nhoras para a defini\u00e7\u00e3o dos seus resultados, postergando o diagn\u00f3stico e \n\no tratamento adequado.\n12\n\n Portanto, outros par\u00e2metros cl\u00ednicos e \n\nlaboratoriais s\u00e3o necess\u00e1rios para a identifica\u00e7\u00e3o precoce de infec\u00e7\u00e3o \n\nneste grupo de pacientes. \n\n\n\n22 \n\n \n\nAssim, biomarcadores inflamat\u00f3rios, como a prote\u00edna C reativa \n\n(PCR) e a  procalcitonina (PCT) t\u00eam auxiliado no diagn\u00f3stico \n\ndiferencial nos pacientes com suspeita de infec\u00e7\u00e3o.\n13-15\n\n Sabe-se que a \n\nPCR aumenta rapidamente em resposta a processos inflamat\u00f3rios n\u00e3o \n\nespec\u00edficos, sendo produzida predominantemente pelos hepat\u00f3citos.\n16,17\n\n \n\nDessa maneira, a sua interpreta\u00e7\u00e3o poderia estar equivocada quando \n\nutilizada em pacientes com disfun\u00e7\u00e3o hep\u00e1tica que s\u00e3o admitidos com \n\nquadros infecciosos.\n18,19\n\n Apesar disso, estudos demonstraram que a PCR \n\n\u00e9 um marcador confi\u00e1vel para o diagn\u00f3stico diferencial de infec\u00e7\u00e3o \n\nbacteriana nos pacientes portadores de hepatopatia cr\u00f4nica.\n20-22\n\n  \n\nDe forma semelhante \u00e0 PCR, a PCT \u00e9 produzida principalmente  \n\npelo f\u00edgado em situa\u00e7\u00f5es cl\u00ednicas que levam \u00e0 s\u00edndrome da resposta \n\ninflamat\u00f3ria sist\u00eamica (SIRS).\n23,24\n\n Durante a infec\u00e7\u00e3o, PCT \u00e9 um \u00f3timo \n\nmarcador na diferencia\u00e7\u00e3o entre infec\u00e7\u00e3o bacteriana de infec\u00e7\u00e3o viral ou \n\ninflama\u00e7\u00e3o de origem n\u00e3o infecciosa.\n25\n\n No entanto, sua concentra\u00e7\u00e3o \n\npode estar elevada em condi\u00e7\u00f5es n\u00e3o relacionadas \u00e0 infecc\u00e3o, como por \n\nexemplo, traumatismos, cirurgias de grande porte, queimaduras e \n\nchoque cardiog\u00eanico.\n26,27\n\n \n\nA  elevada frequ\u00eancia de infec\u00e7\u00e3o como causa da interna\u00e7\u00e3o \n\nhospitalar de pacientes com cirrose hep\u00e1tica descompensada justifica a \n\nbusca por biomarcadores que possam favorecer seu diagn\u00f3stico precoce, \n\nviabilizando seu tratamento adequado.  Al\u00e9m disso, h\u00e1 a possibilidade \n\ndesses testes laboratoriais servirem tamb\u00e9m como potenciais marcadores \n\npreditivos de mortalidade, tornando-se  ferramentas importantes durante \n\na admiss\u00e3o e a interna\u00e7\u00e3o hospitalar nesta popula\u00e7\u00e3o. Neste contexto, o \n\nobjetivo deste estudo foi avaliar a  efetividade da PCR e da PCT como \n\nmarcadores de infec\u00e7\u00e3o na admiss\u00e3o hospitalar de pacientes com cirrose \n\nhep\u00e1tica descompensada e como preditores de mortalidade no s\u00e9timo dia \n\ne no terceiro m\u00eas ap\u00f3s a admiss\u00e3o.   \n\n \n\n  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n23 \n\n \n\n2. M\u00c9TODOS \n \n\n2.1 DELINEAMENTO DO ESTUDO \n \n\nTrata-se de um estudo prospectivo, que incluiu todos os pacientes \n\ncom diagn\u00f3stico de cirrose hep\u00e1tica descompensada, admitidos no \n\nservi\u00e7o de emerg\u00eancia do Hospital Universit\u00e1rio Polydoro Ernani S\u00e3o \n\nThiago, da Universidade Federal de Santa Catarina \u2013 HU/UFSC, no \n\nper\u00edodo de dezembro de 2010 a novembro de 2011. O estudo foi \n\naprovado pelo Comit\u00ea de \u00c9tica em Pesquisa com Seres Humanos da \n\nUFSC (ANEXO A) e encontra-se protocolado sob o n\u00famero 1822/2011. \n\n Na admiss\u00e3o hospitalar, os indiv\u00edduos que assinaram o termo de \n\nconsentimento livre e esclarecido (TCLE) (AP\u00caNDICE A) responderam \n\num question\u00e1rio que foi aplicado por um dos pesquisadores \n\n(AP\u00caNDICE B).  \n\nA avalia\u00e7\u00e3o da mortalidade no s\u00e9timo dia e no terceiro m\u00eas ap\u00f3s \n\na admiss\u00e3o hospitalar foi realizada quando os pacientes receberam alta \n\nhospitalar por meio de contato telef\u00f4nico.  \n\n \n\n2.2   SUJEITOS  \n\n \n\nTodos os indiv\u00edduos com hepatopatia cr\u00f4nica descompensada \n\nmaiores de 18 anos foram inclu\u00eddos no estudo. O diagn\u00f3stico de cirrose \n\nhep\u00e1tica foi estabelecido por meio de an\u00e1lise histol\u00f3gica, quando \n\ndispon\u00edvel, ou pela combina\u00e7\u00e3o de achados cl\u00ednicos, laboratoriais e de \n\nimagem. \n\n Foram exclu\u00eddos os pacientes internados para a realiza\u00e7\u00e3o de \n\nprocedimentos eletivos e aqueles indiv\u00edduos que receberam antibi\u00f3tico \n\nnum per\u00edodo maior que 12 horas antes da coleta dos exames \n\nlaboratoriais.  \n\nPara fins de an\u00e1lise, os pacientes que foram submetidos ao \n\ntransplante hep\u00e1tico durante o acompanhamento foram inclu\u00eddos no \n\ngrupo de \u00f3bitos. \n\n \n\n2.3 INSTRUMENTOS E T\u00c9CNICAS DE COLETAS DE DADOS \n \n\nOs pacientes foram avaliados nas primeiras 12 horas de \n\ninterna\u00e7\u00e3o por um dos pesquisadores envolvidos, e as seguintes \n\nvari\u00e1veis cl\u00ednicas foram coletadas: idade, g\u00eanero, ra\u00e7a, etilismo atual, \n\n\n\n24 \n\n \n\nuso de drogas il\u00edcitas, doen\u00e7as associadas, uso de antibi\u00f3tico profil\u00e1tico, \n\netiologia da cirrose, descompensa\u00e7\u00e3o pr\u00e9via e atual. Todos os pacientes \n\nforam submetidos \u00e0 avalia\u00e7\u00e3o laboratorial no momento da admiss\u00e3o, \n\nsendo considerados para o estudo: leuc\u00f3citos totais, neutr\u00f3filos, s\u00f3dio, \n\ncreatinina, albumina, bilirrubina total, rela\u00e7\u00e3o normatizada internacional \n\n(RNI), PCR. Uma al\u00edquota de soro das amostras coletadas no momento \n\nda interna\u00e7\u00e3o foi estocada a  \n\n-20\u00ba C para dosagem da PCT que foi realizada ao final da coleta \n\ndos dados. \n\nOs indiv\u00edduos com suspeita de infec\u00e7\u00e3o na admiss\u00e3o hospitalar \n\nforam submetidos \u00e0 investiga\u00e7\u00e3o cl\u00ednica para confirma\u00e7\u00e3o deste \n\ndiagn\u00f3stico, bem como para definir o foco prim\u00e1rio. An\u00e1lise \n\nretrospectiva do prontu\u00e1rio m\u00e9dico tamb\u00e9m foi realizada em todos os \n\npacientes do estudo para avaliar a presen\u00e7a de infec\u00e7\u00e3o.  \n\nOs crit\u00e9rios utilizados para o diagn\u00f3stico de infec\u00e7\u00e3o \n\n(pneumonia, infec\u00e7\u00e3o de pele, infec\u00e7\u00e3o do trato urin\u00e1rio e gastroenterite) \n\nseguiram a defini\u00e7\u00e3o do \u201cCenter for Diseases Control\u201d (CDC).\n28 \n\n(ANEXO B)  O diagn\u00f3stico de peritonite bacteriana espont\u00e2nea (PBE) \n\nfoi realizado quando a contagem de neutr\u00f3filos do l\u00edquido asc\u00edtico foi \n\nmaior ou igual a 250 neutr\u00f3filos por mm\n3\n, independentemente da cultura \n\nnegativa, e na aus\u00eancia de foco infeccioso intra-abdominal.\n29\n\n \n\nConsiderou-se bacterascite quando a contagem de neutr\u00f3filos do l\u00edquido \n\nasc\u00edtico foi inferior que 250 c\u00e9lulas por mm\n3\n, por\u00e9m com cultura \n\npositiva.\n29\n\n  \n\nO diagn\u00f3stico de s\u00edndrome da resposta inflamat\u00f3ria sist\u00eamica \n\n(SIRS) assim como o de sepse foi estabelecido a partir da defini\u00e7\u00e3o da \n\n\u201cAmerican College of Chest Physicians/Society Of Critical Care \nMedicine\u201d (ACCP/SCCM) e foram baseados nos crit\u00e9rios diagn\u00f3sticos \n\ndo comit\u00ea da Confer\u00eancia de Consenso de 1992.\n30\n\n (ANEXO C) \n\nA encefalopatia hep\u00e1tica foi graduada de acordo com os crit\u00e9rios \n\nde West-Haven.\n31 \n\n(ANEXO D) A gravidade da doen\u00e7a hep\u00e1tica na \n\nadmiss\u00e3o foi estimada atrav\u00e9s da classifica\u00e7\u00e3o de Child-Pugh\n32\n\n \n\n(ANEXO E) e do modelo MELD (Model for End-Stage Liver \n\nDisease),\n33\n\n (ANEXO F) calculados com base nos exames laboratoriais \n\ndo dia da admiss\u00e3o. \n\n \n\n2.4 DETERMINA\u00c7\u00c3O DOS N\u00cdVEIS DA PROTE\u00cdNA C REATIVA E \nDA PROCALCITONINA \n\n \n\n\n\n25 \n\n \n\n A dosagem da PCR e da PCT foi realizada em amostras \n\ncoletadas na admiss\u00e3o hospitalar. Utilizou-se a t\u00e9cnica de \n\nimunonefelometria para avaliar as concentra\u00e7\u00f5es s\u00e9ricas da PCR, com o \n\nreagente CardioPhase\n\u00ae\n hsCRP e o equipamento Siemens BNII. Essa \n\nmetodologia tem sensibilidade anal\u00edtica de 0,175 mg/L.  \n\nA an\u00e1lise quantitativa da PCT foi realizada em um laborat\u00f3rio \n\nprivado e sua concentra\u00e7\u00e3o foi determinada por meio da t\u00e9cnica de \n\nimunoquimioluminesc\u00eancia. Realizou-se a an\u00e1lise utilizando o \n\nequipamento Siemens Advia Centaur XP e o reagente ADVIA Centaur \n\nBRAHMS PCT. Os limites de quantifica\u00e7\u00e3o desta t\u00e9cnica s\u00e3o de 0,02 \n\nng/ml a 75 ng/ml. \n\n \n\n2.5 AN\u00c1LISE ESTAT\u00cdSTICA \n\n \n Foi efetuado o teste de Kolmogorov-Smirnov para avaliar a \n\nnormalidade da distribui\u00e7\u00e3o das vari\u00e1veis. As vari\u00e1veis cont\u00ednuas foram \n\ncomparadas por meio dos testes t de Student no caso de distribui\u00e7\u00e3o \n\nnormal ou Mann-Whitney nos demais casos. As vari\u00e1veis categ\u00f3ricas \n\nforam avaliadas pelo teste qui-quadrado. A acur\u00e1cia diagn\u00f3stica dos \n\nmarcadores de fase aguda foi analisada atrav\u00e9s de curvas ROC (receiver \n\noperating characteristics) e atrav\u00e9s do c\u00e1lculo da sensibilidade, \n\nespecificidade, valores preditivos positivo e negativo para os pontos de \n\ncorte escolhidos. Valores de p menor que 0,05 foram considerados \n\nestatisticamente significativos. Todos os testes utilizados s\u00e3o bi-caudais \n\ne foram executados pelo programa estat\u00edstico SPSS, vers\u00e3o 17.0 (SPSS, \n\nChicago, IL, EUA). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n26 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n27 \n\n \n\n3. RESULTADOS \n\n \n\n3.1 CARACTER\u00cdSTICAS DA CASU\u00cdSTICA \n\n \n\nForam avaliadas todas as admiss\u00f5es hospitalares por cirrose \n\nhep\u00e1tica descompensada ocorridas no per\u00edodo entre dezembro de 2010 e \n\nnovembro de 2011. Vinte delas foram exclu\u00eddas do estudo tendo em \n\nvista que a coleta dos exames ocorreu 12 horas ap\u00f3s o in\u00edcio da \n\nantibioticoterapia. Sendo assim, foram eleg\u00edveis para a pesquisa 64 \n\npacientes, totalizando 81 interna\u00e7\u00f5es.  \n\n As caracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos pacientes \n\nestudados est\u00e3o descritas na Tabela 1. Para os pacientes que internaram \n\nmais de uma vez, foram utilizados os dados da primeira interna\u00e7\u00e3o \n\nhospitalar. A m\u00e9dia de idade foi de 54,31 \u00b1 11,87 anos, sendo a maioria \n\ndo g\u00eanero masculino (68,8%) e da ra\u00e7a branca (87,5%). Consumo atual \n\nde \u00e1lcool e hist\u00f3ria de uso de drogas il\u00edcitas foi relatado por 46,9% e \n\n6,5% dos pacientes, respectivamente. As principais causas de cirrose \n\nhep\u00e1tica foram v\u00edrus da hepatite C e \u00e1lcool, presentes em 28 (43,8%) e \n\n19 (29,7%) pacientes, respectivamente. Epis\u00f3dio pr\u00e9vio de \n\ndescompensa\u00e7\u00e3o da doen\u00e7a hep\u00e1tica foi referido por 37 (59,7%) \n\npacientes, e dois (3,1%) faziam uso de antibi\u00f3tico profil\u00e1tico.  \n\n \n\n3.2 FATORES ASSOCIADOS \u00c0 PRESEN\u00c7A DE INFEC\u00c7\u00c3O NA \n\nADMISS\u00c3O HOSPITALAR \n\n \n\n Vinte e quatro pacientes (29,6%) apresentaram infec\u00e7\u00e3o e 13 \n\n(54,2%) deles sinais de sepse. As infec\u00e7\u00f5es mais frequentes foram \n\nperitonite bacteriana espont\u00e2nea e infec\u00e7\u00e3o do trato urin\u00e1rio, em 10 \n\n(41,7%) e 4 (16,7%) admiss\u00f5es por descompensa\u00e7\u00e3o da cirrose, \n\nrespectivamente. Pneumonia e infec\u00e7\u00e3o de pele foram encontradas em \n\noutras 6 (25,0%) admiss\u00f5es. A tabela 2 descreve quais foram os focos \n\nde infec\u00e7\u00e3o encontrados no momento da admiss\u00e3o hospitalar. Infec\u00e7\u00e3o \n\nfoi confirmada por cultura em 14 (58,3%) admiss\u00f5es, sendo que as \n\nbact\u00e9rias isoladas mais frequentes foram Escherichia coli e \n\nEnterococcus sp. (Tabela 3). \n \n\n \n\n \n\n \n\n\n\n28 \n\n \n\nTabela 1. Caracter\u00edsticas cl\u00ednicas e epidemiol\u00f3gicas dos pacientes \n\ninternados com cirrose hep\u00e1tica descompensada* \n\nVari\u00e1veis \n\n \n\nPacientes inclu\u00eddos \n\n(n = 64) \n\nIdade (anos); m\u00e9dia \u00b1 DP (mediana) 54,31 \u00b1 11,87 (55,0) \n\nSexo masculino, n (%) 44 (68,8) \n\nRa\u00e7a branca, n (%) 56 (87,5) \n\nEtilismo atual\n\u00b6\n n (%) 30 (46,9) \n\nCausa da cirrose, n (%)  \n\nHepatite C 28 (43,8) \n\nHepatite B 4 (6,3) \n\n\u00c1lcool 19 (29,7) \n\nHepatite auto-imune 1 (1,6) \n\nOutros 12 (18,8) \n\nDescompensa\u00e7\u00e3o hep\u00e1tica pr\u00e9via, n \n\n(%) \n\n37 (57,8) \n\nDiabetes mellitus, n (%) 16 (25) \n\nInfec\u00e7\u00e3o pelo HIV, n (%) 1 (1,6) \n\nUso de antibi\u00f3tico profil\u00e1tico, n (%) 2 (3,1) \n\nUso de drogas il\u00edcitas, n (%) 4 (6,25) \n\nDP = desvio-padr\u00e3o. HIV = V\u00edrus da imunodefici\u00eancia humana. * Para \n\nos pacientes que internaram mais de uma vez, foram utilizados somente \n\nos dados da primeira interna\u00e7\u00e3o hospitalar. \n\u00b6 \n\nConsumo di\u00e1rio de > 20 \n\ngramas de \u00e1lcool no \u00faltimo m\u00eas antes da admiss\u00e3o hospitalar.  \n\n \n\nA tabela 4 exibe a compara\u00e7\u00e3o entre o grupo de pacientes \n\ninfectados e n\u00e3o infectados. A mediana da idade foi semelhante entre os \n\ngrupos. Por outro lado, os pacientes infectados apresentavam valores \n\nsignificativamente maiores no escore MELD e maior propor\u00e7\u00e3o de \n\nindiv\u00edduos classificados como classe C de Child-Pugh. Quanto \u00e0s \n\nmanifesta\u00e7\u00f5es cl\u00ednicas da cirrose hep\u00e1tica descompensada, n\u00e3o houve \n\ndiferen\u00e7a na presen\u00e7a de encefalopatia hep\u00e1tica (p = 0,306) ou de \n\nhttp://pt.wikipedia.org/wiki/V%C3%ADrus_da_imunodefici%C3%AAncia_humana\n\n\n29 \n\n \n\nhemorragia digestiva alta (p = 0,943), enquanto a ascite e SIRS foram \nmais frequentes nos pacientes infectados (p = 0,004 e p = 0,019, \n\nrespectivamente).  \n\nOs resultados dos exames laboratoriais observados nos pacientes \n\ncirr\u00f3ticos s\u00e3o mostrados na tabela 4. Quanto \u00e0s medianas dos valores de \n\nleuc\u00f3citos totais e neutr\u00f3filos, foram significativamente maiores nos \n\npacientes com infec\u00e7\u00e3o (p = 0,049 e p = 0,016, respectivamente). O \n\nvalor da mediana da creatinina e da RNI foi maior nos pacientes com \n\ninfec\u00e7\u00e3o (p = 0,003 e p = 0,004, respectivamente). A m\u00e9dia das \n\nconcentra\u00e7\u00f5es s\u00e9ricas de albumina foram mais baixas nos pacientes \n\ninfectados (p &lt;0,001), por\u00e9m n\u00e3o houve diferen\u00e7a nas concentra\u00e7\u00f5es \ns\u00e9ricas de s\u00f3dio (p = 0,517) e bilirrubinas totais (p = 0,132) entre os \n\ngrupos. \n\n \n\nTabela 2. Focos de infec\u00e7\u00e3o observados nos pacientes com cirrose \n\nhep\u00e1tica descompensada que foram admitidos na unidade de emerg\u00eancia \n\nhospitalar \n\nFocos de infec\u00e7\u00e3o n (%) \n\nPeritonite bacteriana espont\u00e2nea 10 (41,7%) \n\nInfec\u00e7\u00e3o do trato urin\u00e1rio 4 (16,7%) \n\nPneumonia 3 (12,5%) \n\nInfec\u00e7\u00e3o de pele 3 (12,5%) \n\nInfec\u00e7\u00e3o sem foco identificado 2 (8,3%) \n\nGastroenterite 1 (4,2%) \n\nBacterascite 1 (4,2%) \n\nTotal 24 (100%) \n\n \n\n \n\nAs medianas dos n\u00edveis s\u00e9ricos de PCR e PCT nos pacientes \n\ninclu\u00eddos foram de 12,3 mg/L (m\u00e9dia 47,02 \u00b1 69,95 mg/L) e 0,35 ng/ml \n\n(m\u00e9dia 2,93 \u00b1 7,16). Foram observadas concentra\u00e7\u00f5es mais elevadas das \n\nmedianas dos marcadores inflamat\u00f3rios nos cirr\u00f3ticos infectados no \n\nmomento da admiss\u00e3o hospitalar quando comparados aos demais (PCR \n\nmediana: 81,55 vs. 6,78 mg/L; p &lt;0,001 e PCT mediana: 2,50 vs. 0,19 \n\nng/ml; p &lt;0,001). \n\n \n\n \n\n\n\n30 \n\n \n\nTabela 3. Microorganismos isolados em 81 admiss\u00f5es hospitalares de \n\npacientes com cirrose hep\u00e1tica descompensada \n\nMicroorganismos*  n (%)  \n\n  \n\nEscherichia coli 5 (25) \n\nEnterococcus sp. 5 (25) \n\nKlebsiela pneumoniae 3 (15) \n\nStaphylococcus sp. 3 (15) \n\nStreptococcus sp. 3 (15) \n\nMorganella morganii 1 (5) \n\nTotal        20  (100) \n\n*5 pacientes apresentavam mais de um microorganismo na mesma \n\ncultura \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n31 \n\n \n\nTabela 4. Vari\u00e1veis cl\u00ednicas e laboratoriais associadas \u00e0 infec\u00e7\u00e3o na \n\nadmiss\u00e3o  \n\nVari\u00e1veis \n\nAus\u00eancia  \n\nde infec\u00e7\u00e3o \n\n(n = 57) \n\nPresen\u00e7a de \n\ninfec\u00e7\u00e3o \n\n(n = 24) \n\np \n\nM\u00e9dia de idade (anos) \u00b1 DP 54,58 \u00b1 11,93 54,17 \u00b1 13,28 0,891 \n\nAscite, n (%)  23 (40,4) 18 (75) 0,004 \n\nEncefalopatia, n (%)  31 (54,4) 16 (66,7) 0,306 \n\nHDA, n (%)\n \n\n28 (49,1) 12 (50,0) 0,943 \n\nClassifica\u00e7\u00e3o Child-Pugh, n (%)    0,027 \n\nA 9 (15,8%) 0 (0)  \n\nB 28 (49,1) 9 (37,5)  \n\nC 20 (35,1) 15 (62,5) 0,023 \n\nMELD, m\u00e9dia \u00b1 DP  14,74 \u00b1 5,99  20,29 \u00b1 6,25 &lt;0,001 \n\nSIRS, n (%) 15 (28,6) 13 (54,2) 0,019 \n\nTax >38,0\no\nC ou&lt;36,0\n\no\nC, n (%) 11(19,6) 4 (16,7) 1,00 \n\nLeuc\u00f3citos totais (mm\n3\n), \n\nmediana \n\n7.035 10.040 0,049 \n\nNeutr\u00f3filos (mm\n3\n), mediana 4.343 8.112 0,016 \n\nS\u00f3dio (mEq/L), m\u00e9dia \u00b1 DP 134,64 \u00b1 4,81 133,87 \u00b1 4,77 0,517 \n\nCreatinina (mg/dL), mediana 1,00 1,70 0,003 \n\nRNI, mediana 1,38 1,53 0,004 \n\nAlbumina (g/dL), m\u00e9dia \u00b1 DP 2,54 \u00b1 0,64 1,87 \u00b1 0,39 &lt;0,001 \n\nBilirrubina total (mg/dL), \n\nmediana \n\n1,66 2,80 0,132 \n\nPCR (mg/l),mediana 6,78 81,55 &lt;0,001 \n\nPCT (ng/ml) mediana 0,19 2,50 &lt;0,001 \n\n DP = Desvio padr\u00e3o. HDA = hemorragia digestiva alta.  MELD = Model for End-\n\nStage Liver Disease. SIRS = s\u00edndrome da resposta inflamat\u00f3ria sist\u00eamica. RNI = \n\nrela\u00e7\u00e3o normatizada internacional. PCR = prote\u00edna C reativa. PCT = procalcitonina.  \n\nTax = temperatura axilar. \n\n \n\n\n\n32 \n\n \n\n3.3  EFETIVIDADE DA PROTE\u00cdNA C REATIVA E DA \n\nPROCALCITONINA NO DIAGN\u00d3STICO DE INFEC\u00c7\u00c3O NA \n\nADMISS\u00c3O HOSPITALAR \n\n \n\n A efetividade das concentra\u00e7\u00f5es s\u00e9ricas da PCR e da PCT no \n\ndiagn\u00f3stico de infec\u00e7\u00e3o foi avaliada por curva ROC. Todas as \n\ninterna\u00e7\u00f5es foram inclu\u00eddas para a an\u00e1lise da acur\u00e1cia da PCT, em \n\ncontrapartida, para a an\u00e1lise da PCR, foi poss\u00edvel incluir 75 admiss\u00f5es, \n\ntendo em vista que em 6 casos, a coleta deste marcador n\u00e3o foi \n\nrealizada no momento da admiss\u00e3o. A figura 1 mostra a acur\u00e1cia dos \n\ndois marcadores. As \u00e1reas sob a curva ROC da PCR e da PCT para o \n\ndiagn\u00f3stico de infec\u00e7\u00e3o foram 0,835 \u00b1 0,052 e 0,856 \u00b1 0,047, \n\nrespectivamente. \n\n Tr\u00eas pontos de corte foram utilizados para an\u00e1lise e obten\u00e7\u00e3o \n\nda acur\u00e1cia diagn\u00f3stica da PCR, de acordo com a curva ROC (tabela \n\n5). Quando foi estabelecido o valor de 5 mg/L como ponto de corte no \n\ndiagn\u00f3stico de infec\u00e7\u00e3o, encontrou-se acur\u00e1cia de 53% com \n\nsensibilidade de 96% e especificidade de 36%. A utiliza\u00e7\u00e3o do ponto \n\nde corte de 10 mg/L apresentou acur\u00e1cia de 69%, com sensibilidade e \n\nespecificidade de 86% e 62%, respectivamente.  A acur\u00e1cia, \n\nsensibilidade e especificidade foram, respectivamente, 81%, 82% e \n\n81% quando se utilizou o valor de 29,5 mg/L. \n\n De forma semelhante, tr\u00eas pontos de corte da PCT foram \n\nutilizados na avalia\u00e7\u00e3o da efetividade no diagn\u00f3stico de infec\u00e7\u00e3o \n\n(tabela 5). Valor de corte de 0,10 ng/ml apresentou acur\u00e1cia de 57%, \n\nsensibilidade de 96% e especificidade de 40%. Quando se avaliou o \n\nn\u00edvel de 0,5 ng/ml, evidenciou uma acur\u00e1cia de 78%, com \n\nsensibilidade e especificidade de 75% e 79%, respectivamente. Ponto \n\nde corte de 1,1 ng/ml mostrou acur\u00e1cia de 83%, sensibilidade de 67% e \n\nespecificidade de 90%. \n\n \n\n3.4 ASSOCIA\u00c7\u00c3O ENTRE A PROTE\u00cdNA C REATIVA E A \nPROCALCITONINA COM A MORTALIDADE EM SETE DIAS E \n\nTR\u00caS MESES AP\u00d3S A ADMISS\u00c3O HOSPITALAR \n\n \n\n Com rela\u00e7\u00e3o \u00e0s concentra\u00e7\u00f5es da PCR e a classifica\u00e7\u00e3o de \n\nChild-Pugh, o estudo demonstrou tend\u00eancia de aumento no valor da \n\nmediana da PCR quando foram comparadas a combina\u00e7\u00e3o das classes A \n\ne B com a classe C (8,6 mg/L vs. 29,5 mg/L p = 0,084). Por outro lado, \n\n\n\n33 \n\n \n\na mediana das concentra\u00e7\u00f5es da PCT foi significativamente maior (p = \n0,002) no grupo Child C (0,57 ng/ml) do que no grupo combinado Child  \n\nA + B (0,19 ng/ml). Valores de mediana da PCR e da PCT \n\ntamb\u00e9m foram relacionadas com o escore MELD. Pacientes com \n\npontua\u00e7\u00e3o MELD &lt;15 evidenciaram menores concentra\u00e7\u00f5es da PCR \n\ncom mediana de 6,6 mg/L, enquanto o grupo com escore MELD ? 15 \n\napresentou mediana de 41,1 (p = 0,002). Observaram-se resultados \n\nsemelhantes quando foram comparadas as medianas da PCT. O grupo \n\ncom MELD &lt;15 apresentou mediana de 0,17, j\u00e1 o valor de 0,89 foi \n\nencontrado no grupo com MELD ? 15 (p &lt;0,001). \n\n \n\n     \n\n \n\n \n\n \n\n \n\n \n\nFigura 1. Curvas ROC da prote\u00edna C reativa (PCR) e da procalcitonina \n\n(PCT) para o diagn\u00f3stico de infec\u00e7\u00e3o na admiss\u00e3o hospitalar. A \u00e1rea sob \n\na curva representa o poder dos testes. \n\n \n\n\n\n34 \n\n \n\nTabela 5. Efetividade dos pontos de corte da prote\u00edna C reativa e da \n\nprocalcitonina no diagn\u00f3stico de infec\u00e7\u00e3o durante a admiss\u00e3o hospitalar \n\n \nPontos de \n\ncorte \n\nAcur\u00e1cia \n\n(%) \n\nS \n\n(%) \n\nE \n\n(%) \n\nVPP \n\n (%) \n\nVPN  \n\n(%) \n\n           \n0,10 57 96 40 40 96 \n\nPCT 0,50 78 75 79 60 88 \n\n 1,10 83 67 90 73 86 \n\n \n\n \n5,0 53 96 36 38 95 \n\nPCR 10.0 69 86 62 49 92 \n\n 29,6 81 82 81 64 92 \n\nPCT = Procalcitonina (ng/ml). PCR = Prote\u00edna C reativa (mg/L).  \n\nS = sensibilidade. E = especificidade. VPP = valor preditivo positivo. \n\nVPN = valor preditivo negativo.  \n\n \n\n \n\nPara a avalia\u00e7\u00e3o da mortalidade dos pacientes admitidos mais de \n\numa vez, levou-se em considera\u00e7\u00e3o somente a \u00faltima interna\u00e7\u00e3o. Dez \n\npacientes (15,6%) faleceram at\u00e9 o s\u00e9timo dia ap\u00f3s a admiss\u00e3o \n\nhospitalar. N\u00e3o foram observadas diferen\u00e7as na propor\u00e7\u00e3o de \n\nindiv\u00edduos infectados quando os pacientes que morreram foram \n\ncomparados aos que sobreviveram (20,0% vs. 27,3%, p = 1,00). \n\nQuando avaliados ap\u00f3s 90 dias da admiss\u00e3o, 22 indiv\u00edduos (34,9%) \n\nfaleceram e um paciente foi exclu\u00eddo da an\u00e1lise devido \u00e0 perda do \n\nacompanhamento. A propor\u00e7\u00e3o de infectados entre os que faleceram \n\nno acompanhamento de 90 dias ap\u00f3s a admiss\u00e3o hospitalar foi \n\nnumericamente superior quando comparada aos que sobreviveram, \n\npor\u00e9m sem diferen\u00e7a estat\u00edstica (36,4% vs. 19,0% p = 0,129). \n\n\n\n35 \n\n \n\n \n\nAs dosagens da PCR e da PCT tamb\u00e9m foram relacionadas com \n\no \u00f3bito no s\u00e9timo dia e no terceiro m\u00eas ap\u00f3s a admiss\u00e3o hospitalar \n\n(Tabela 6). N\u00e3o foi observada diferen\u00e7a entre a mediana da PCR e o \n\n\u00f3bito no s\u00e9timo dia (p = 0,531). No entanto, notou-se diferen\u00e7a \n\nsignificativa no valor da mediana da PCT quando relacionada ao \u00f3bito \n\nem sete dias (0,22 vs. 0,94 p = 0,009). Na compara\u00e7\u00e3o das medianas da \n\nPCR e da PCT com o \u00f3bito em tr\u00eas meses ap\u00f3s a interna\u00e7\u00e3o, \n\nevidenciou-se diferen\u00e7a com signific\u00e2ncia estat\u00edstica para os dois \n\nmarcadores (PCR 7,04 vs. 41,05 p = 0,026 e PCT 0,16 vs. 0,94 p = \n\n0,001).  \n\n \n\n \n\nTabela 6. Rela\u00e7\u00e3o da prote\u00edna C reativa e da procalcitonina com o \u00f3bito \n\nno s\u00e9timo dia e no terceiro m\u00eas ap\u00f3s a admiss\u00e3o hospitalar \n\n \n\u00d3bito 7 dias \n\n(n:10) \n  \n\n N\u00e3o Sim p \n\nPCR \n\nmg/L (mediana) \n9,0 33,15 0,531 \n\nPCT \n\n ng/ml (mediana) \n0,22 0,94 0,009 \n\n \n\u00d3bito 3 meses*  \n\n(n: 22) \n  \n\n N\u00e3o Sim p \n\nPCR \n\n mg/L (mediana) \n7,04 41,05 0,026 \n\nPCT, \n\nng/ml (mediana) \n0,16 0,94 0,001 \n\n \n\n4 DISCUSS\u00c3O \n\n \n\n \n\n \n\nAbrevia\u00e7\u00f5es: PCR = prote\u00edna C reeativa. PCT = procalcitonina. \n\n*Houve perda de contato com um paciente, no acompanhamento de 3 \n\nmeses.  \n\n \n\n\n\n36 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n37 \n\n \n\n4.DISCUSS\u00c3O \n\n \n\nO diagn\u00f3stico de cirrose hep\u00e1tica representa impacto negativo \n\nconsider\u00e1vel, aumentando o risco de sepse, fal\u00eancia respirat\u00f3ria aguda e \n\nmorte durante a interna\u00e7\u00e3o hospitalar.\n34\n\n Dessa maneira, diagn\u00f3stico e \n\ntratamento precoces s\u00e3o essenciais para proporcionar um progn\u00f3stico \n\nmais favor\u00e1vel a estes indiv\u00edduos.\n35\n\n  \n\nUm estudo prospectivo multic\u00eantrico avaliou mais de 400 \n\nadmiss\u00f5es hospitalares de pacientes com cirrose hep\u00e1tica \n\ndescompensada, encontrando uma preval\u00eancia de infec\u00e7\u00e3o de 34%, \n\nsendo que destes, 60% foi diagnosticada no momento da admiss\u00e3o \n\nhospitalar.\n36\n\n Esta porcentagem \u00e9 similar ao resultado encontrado no \n\nnosso estudo que evidenciou uma preval\u00eancia de infec\u00e7\u00e3o bacteriana de \n\n29,6% no momento da admiss\u00e3o hospitalar. Tandon e colaboradores \n\nobservaram que a gravidade da doen\u00e7a hep\u00e1tica cr\u00f4nica, avaliada por \n\nmeio das concentra\u00e7\u00f5es s\u00e9ricas de albumina e da classifica\u00e7\u00e3o de Child-\n\nPugh, \u00e9 um preditor independente de infec\u00e7\u00e3o entre os cirr\u00f3ticos.\n10\n\n  A \n\nassocia\u00e7\u00e3o entre infec\u00e7\u00e3o e a classifica\u00e7\u00e3o C de Child-Pugh, escore \n\nMELD elevado, baixas concentra\u00e7\u00f5es s\u00e9ricas de albumina e \n\nprolongamento do tempo de protrombina tamb\u00e9m foi observada no \n\nnosso estudo, indicando que a deteriora\u00e7\u00e3o da fun\u00e7\u00e3o hep\u00e1tica \n\npossivelmente est\u00e1 relacionada \u00e0 ocorr\u00eancia de infec\u00e7\u00e3o.  \n\nA transloca\u00e7\u00e3o bacteriana \u00e9 comum em pacientes cirr\u00f3ticos com \n\nascite.\n37\n\n Pacientes com hepatopatia cr\u00f4nica avan\u00e7ada, classe C de Child-\n\nPugh, apresentam mais epis\u00f3dios de transloca\u00e7\u00e3o bacteriana que os \n\ndemais cirr\u00f3ticos.\n38\n\n Este dist\u00farbio leva \u00e0 ativa\u00e7\u00e3o de mon\u00f3citos e \n\nlinf\u00f3citos e o aumento das concentra\u00e7\u00f5es s\u00e9ricas de citocinas \n\nproinflamat\u00f3rias, como o fator de necrose tumoral alfa (TNF-?)\n39\n\n. \n\nPortanto, epis\u00f3dios repetitivos de endotoxemia podem contribuir para o \n\ndesequil\u00edbrio do sistema circulat\u00f3rio e imune dos pacientes cirr\u00f3ticos \n\ncom ascite.\n39\n\n Papp e colaboradores observaram uma preval\u00eancia maior \n\nde ascite entre os pacientes com hepatopatia cr\u00f4nica que estavam \n\ninfectados do que naqueles cirr\u00f3ticos sem infec\u00e7\u00e3o.\n21\n\n No nosso trabalho, \n\ntamb\u00e9m se observou esta associa\u00e7\u00e3o, sendo que os pacientes com ascite \n\napresentaram mais infec\u00e7\u00e3o na admiss\u00e3o hospitalar do que os cirr\u00f3ticos \n\nsem ascite. \n\n Estudos cl\u00ednicos pr\u00e9vios, envolvendo um n\u00famero vari\u00e1vel de \n\npacientes, encontraram resultados conflitantes quanto \u00e0 an\u00e1lise da PCR \n\ncomo marcador de infec\u00e7\u00e3o nos pacientes cirr\u00f3ticos.\n20-22,40\n\n A acur\u00e1cia \n\n\n\n38 \n\n \n\npara o diagn\u00f3stico de infec\u00e7\u00e3o, avaliada atrav\u00e9s da \u00e1rea sob a curva \n\nROC, variou de 0,79 a 0,93.\n20-22,40\n\n Le Moine e colaboradores estudaram \n\nprospectivamente 57 pacientes com cirrose hep\u00e1tica descompensada, e \n\nconclu\u00edram que a PCR tem valor limitado no diagn\u00f3stico de infec\u00e7\u00e3o \n\nneste grupo de pacientes.\n18\n\n J\u00e1 outro estudo que utilizou o valor de corte \n\nde 5 mg/L, na avalia\u00e7\u00e3o prospectiva de infec\u00e7\u00e3o em indiv\u00edduos \n\ncirr\u00f3ticos, encontrou uma \u00e1rea sob a curva ROC de 0,641.\n41\n\n Um fato \n\ninteressante observado nestes estudos descritos acima, foi a diferen\u00e7a \n\nnos pontos de corte utilizados para identifica\u00e7\u00e3o de infec\u00e7\u00e3o, sendo \n\nencontrado valores de 9,2 mg/L at\u00e9 80 mg/L. Esta grande varia\u00e7\u00e3o nos \n\npontos de corte pode ser explicada pela diferen\u00e7a na gravidade dos \n\nepis\u00f3dios de infec\u00e7\u00e3o entre os estudos, al\u00e9m do pequeno n\u00famero de \n\nindiv\u00edduos estudados. Em um estudo transversal que avaliou 98 \n\npacientes com cirrose hep\u00e1tica admitidos numa unidade de emerg\u00eancia, \n\nsugeriu que o ponto de corte de 24,7 mg/dl \u00e9 o melhor valor para \n\nauxiliar no diagn\u00f3stico de bacteremia e sepse neste grupo de \n\nindiv\u00edduos.\n21\n\n Este ponto de corte apresentou uma acur\u00e1cia para o \n\ndiagn\u00f3stico de sepse de 81%, quando avaliado atrav\u00e9s da curva ROC. \n\nNo nosso estudo, concentra\u00e7\u00f5es da PCR foram superiores entre os \n\npacientes infectados em compara\u00e7\u00e3o aos n\u00e3o infectados, sendo que o \n\nvalor 29,5 mg/L foi o melhor ponto de corte avaliado atrav\u00e9s do \n\nemprego da curva ROC. Neste valor, a acur\u00e1cia para o diagn\u00f3stico de \n\ninfec\u00e7\u00e3o foi de 81% com sensibilidade e especificidade acima de 80%. \n\nPapp e colaboradores avaliaram prospectivamente 368 pacientes com \n\ncirrose hep\u00e1tica admitidos em uma unidade hospitalar.\n21\n\n Estes autores \n\nobservaram que o valor da PCR de 9,2 mg/L \u00e9 o melhor ponto de corte \n\npara o diagn\u00f3stico de infec\u00e7\u00e3o, com uma acur\u00e1cia de 93%. Deve-se \n\nconsiderar que 25% dos pacientes deste estudo apresentavam infec\u00e7\u00f5es \n\nleves e localizadas, principalmente do trato urin\u00e1rio.\n21\n\n Em nosso estudo, \n\nutilizando o ponto de corte da PCR de 10 mg/L, notou-se diminui\u00e7\u00e3o \n\nconsider\u00e1vel da acur\u00e1cia e da especificidade. Um dos fatores que pode \n\nter influenciado a piora da acur\u00e1cia diagn\u00f3stica neste valor de corte foi a \n\npresen\u00e7a de quadros infecciosos graves, j\u00e1 que mais da metade dos \n\npacientes cirr\u00f3ticos admitidos com infec\u00e7\u00e3o apresentavam sinais de \n\nsepse. \n\n  A PCT possui uma propriedade farmacocin\u00e9tica favor\u00e1vel. O \n\nr\u00e1pido pico plasm\u00e1tico (em torno de 6 horas) ap\u00f3s a endotoxemia\n42\n\n \n\nfavorece o diagn\u00f3stico precoce de infec\u00e7\u00e3o bacteriana, auxiliando a \n\nabordagem diagn\u00f3stica e o adequado tratamento dos pacientes com \n\n\n\n39 \n\n \n\nhepatopatia cr\u00f4nica descompensada.  Postula-se que o f\u00edgado seja a \n\nprincipal fonte de PCT durante os epis\u00f3dios infecciosos.\n23,24\n\n Bota e \n\ncolaboradores avaliaram prospectivamente 864 pacientes internados em \n\numa unidade de terapia intensiva, sendo que destes, 79 indiv\u00edduos eram \n\nportadores de cirrose hep\u00e1tica. N\u00e3o foi encontrada diferen\u00e7a entre as \n\nconcentra\u00e7\u00f5es da PCR e da PCT entre pacientes com ou sem cirrose \n\nhep\u00e1tica, sugerindo que, embora o f\u00edgado seja considerado o principal \n\nprodutor destes biomarcadores inflamat\u00f3rios, as concentra\u00e7\u00f5es s\u00e9ricas \n\nn\u00e3o est\u00e3o suprimidas nos pacientes com insufici\u00eancia hep\u00e1tica cr\u00f4nica.\n41\n\n  \n\n  H\u00e1 poucos estudos avaliando a acur\u00e1cia diagn\u00f3stica da PCT em \n\npacientes com doen\u00e7a hep\u00e1tica cr\u00f4nica, por\u00e9m os resultados encontrados \n\nforam favor\u00e1veis.\n20-21,40-41,43-45\n\n Nestes estudos, a \u00e1rea sob a curva ROC \n\nvariou entre 0,68 e 0,98. Connert e colaboradores avaliaram \n\nprospectivamente 127 pacientes com cirrose hep\u00e1tica com ou sem \n\nquadro de descompensa\u00e7\u00e3o.\n43\n\n O ponto de corte de 0,58 ng/ml foi \n\nconsiderado o melhor valor para o diagn\u00f3stico diferencial de infec\u00e7\u00e3o \n\nnos pacientes descompensados\n43\n\n. No estudo de Elefsiniotis e \n\ncolaboradores, a PCT foi dosada em 106 pacientes internados com \n\ndoen\u00e7a hep\u00e1tica aguda ou cr\u00f4nica, sendo que o ponto de corte de 0,5 \n\nng/ml apresentou a melhor acur\u00e1cia no diagn\u00f3stico de infec\u00e7\u00e3o \n\nbacteriana.\n44\n\n No entanto, 46% dos pacientes n\u00e3o infectados com hepatite \n\nalco\u00f3lica e cirrose sobreposta, assim como 30% dos pacientes n\u00e3o \n\ninfectados com hepatite aguda viral, especialmente naqueles com cirrose \n\nou fibrose significante, apresentaram eleva\u00e7\u00f5es leves da PCT. Os \n\nautores conclu\u00edram que \u00e9 necess\u00e1rio empregar um valor de corte maior \n\nque 0,5 ng/ml no diagn\u00f3stico diferencial de infec\u00e7\u00e3o nestes grupos de \n\nindiv\u00edduos com doen\u00e7a hep\u00e1tica. Neste presente estudo, as \n\nconcentra\u00e7\u00f5es s\u00e9ricas da PCT foram significativamente mais elevadas \n\nnos pacientes infectados, mostrando-se efetivas no diagn\u00f3stico de \n\ninfec\u00e7\u00e3o, com uma \u00e1rea sob a curva ROC de 0,86. Quando foi utilizado \n\no ponto de corte de 0,5 ng/ml, a acur\u00e1cia foi de 78%. No entanto, \n\naumentando o limite de corte para 1,1 ng/ml, percebeu-se uma \n\nsuperioridade no desempenho diagn\u00f3stico, com um aumento \n\nconsider\u00e1vel da especificidade. Um dos fatores que pode ter \n\ninfluenciado para a melhoria da efetividade diagn\u00f3stica com o aumento \n\ndo ponto de corte no presente trabalho, foi a piora da fun\u00e7\u00e3o renal entre \n\nos pacientes com cirrose hep\u00e1tica e infec\u00e7\u00e3o. Os cirr\u00f3ticos infectados \n\napresentavam concentra\u00e7\u00f5es s\u00e9ricas significativamente mais elevadas de \n\ncreatinina do que os n\u00e3o infectados, com uma mediana de 1,7 mg/dl. A \n\n\n\n40 \n\n \n\ninfec\u00e7\u00e3o provoca uma resposta inflamat\u00f3ria sist\u00eamica com aumento das \n\nconcentra\u00e7\u00f5es de citocinas pr\u00f3-inflamat\u00f3rias e consequente produ\u00e7\u00e3o de \n\nmediadores vasoativos que podem piorar a fun\u00e7\u00e3o circulat\u00f3ria e causar \n\nfal\u00eancia renal.\n46\n\n Amour e colaboradores investigaram a rela\u00e7\u00e3o entre a \n\nacur\u00e1cia das concentra\u00e7\u00f5es da PCT no diagn\u00f3stico de infec\u00e7\u00e3o p\u00f3s-\n\noperat\u00f3ria e a fun\u00e7\u00e3o renal.\n47\n\n Os autores observaram que a fun\u00e7\u00e3o renal \n\ninfluenciou significativamente as concentra\u00e7\u00f5es s\u00e9ricas da PCT. O \n\nponto de corte para o diagn\u00f3stico de infec\u00e7\u00e3o foi maior naqueles \n\npacientes com disfun\u00e7\u00e3o renal, sendo que o seu desempenho diagn\u00f3stico \n\nfoi significativamente melhor quando o limiar foi ajustado de acordo \n\ncom a fun\u00e7\u00e3o renal. Diante desta variabilidade no ponto de corte da PCT \n\npara o diagn\u00f3stico diferencial de infec\u00e7\u00e3o, estudos prospectivos s\u00e3o \n\nnecess\u00e1rios para avaliar quais s\u00e3o os melhores valores de refer\u00eancia para \n\na confirma\u00e7\u00e3o de infec\u00e7\u00e3o em pacientes com hepatopatia cr\u00f4nica.   \n\n Na presente pesquisa, observou-se rela\u00e7\u00e3o entre as \n\nconcentra\u00e7\u00f5es da PCR e da PCT e a gravidade da hepatopatia cr\u00f4nica. \n\nOs dados mostraram que os indiv\u00edduos com quadro avan\u00e7ado de \n\ndisfun\u00e7\u00e3o hep\u00e1tica (classe C de Child-Pugh) apresentavam medianas \n\nmais elevadas dessas prote\u00ednas de fase aguda do que o restante do grupo \n\n(Child-Pugh A e B). Postula-se que a hepatopatia avan\u00e7ada predisponha \n\no supercrescimento bacteriano, altera\u00e7\u00e3o da permeabilidade intestinal e \n\na transloca\u00e7\u00e3o de bact\u00e9rias e endotoxinas provenientes do intestino.\n6\n \n\nEsta \u00faltima altera\u00e7\u00e3o leva \u00e0 ativa\u00e7\u00e3o de mon\u00f3citos e linf\u00f3citos com \n\nconsequente aumento das concentra\u00e7\u00f5es s\u00e9ricas de citocinas \n\nproinflamat\u00f3rias, como a interleucina-6 (IL-6) e o TNF?.\n39\n\n Ambas est\u00e3o \n\nenvolvidas no in\u00edcio da resposta inflamat\u00f3ria de fase aguda nos \n\nhumanos.\n48\n\n Dessa maneira, bacteremia transit\u00f3ria provavelmente \n\nresultaria em concentra\u00e7\u00f5es s\u00e9ricas elevadas de PCT nos pacientes com \n\nhepatopatia cr\u00f4nica.\n44\n\n A rela\u00e7\u00e3o do aumento da PCR com o avan\u00e7o da \n\ngravidade da hepatopatia cr\u00f4nica, sugerindo a presen\u00e7a de transloca\u00e7\u00e3o \n\nbacteriana foi descrita por Papp e colaboradores, em 2011.\n21\n\n No entanto, \n\nestudos prospectivos futuros necessitam ser realizados para confirmar a \n\nrela\u00e7\u00e3o das concentra\u00e7\u00f5es da PCR e da PCT com a gravidade da \n\nhepatopatia cr\u00f4nica, encontrada no presente estudo.  \n\n N\u00e3o foi observada diferen\u00e7a na preval\u00eancia de mortalidade no \n\ns\u00e9timo dia e no terceiro m\u00eas ap\u00f3s a admiss\u00e3o hospitalar entre os \n\ncirr\u00f3ticos infectados e n\u00e3o infectados no presente estudo. Sabe-se que a \n\ninfec\u00e7\u00e3o provoca uma piora consider\u00e1vel no progn\u00f3stico dos pacientes \n\ncom hepatopatia cr\u00f4nica.\n49\n\n No entanto, a pequena amostra no presente \n\n\n\n41 \n\n \n\nestudo p\u00f4de ter contribu\u00eddo para a semelhan\u00e7a desses resultados entre os \n\ngrupos. \n\n  Neste trabalho, as medianas da PCR e da PCT foram maiores \n\nentre os pacientes que morreram quando comparadas com a mediana \n\ndos sobreviventes ap\u00f3s o acompanhamento de tr\u00eas meses. Papp e \n\ncolaboradores analisaram a rela\u00e7\u00e3o das concentra\u00e7\u00f5es das prote\u00ednas de \n\nfase aguda com a presen\u00e7a de infec\u00e7\u00e3o durante o acompanhamento de \n\num ano.\n21\n\n Estes autores observaram que os pacientes n\u00e3o infectados com \n\nconcentra\u00e7\u00f5es basais de PCR > 10 mg/L apresentaram taxas de infec\u00e7\u00e3o \n\nsignificativamente maiores no per\u00edodo de tr\u00eas meses quando \n\ncomparados aos pacientes com n\u00edveis basais &lt;10 mg/L (p = 0,003), \nsugerindo que a PCR \u00e9 um marcador \u00fatil em predizer a chance de \n\nocorr\u00eancia de infec\u00e7\u00e3o bacteriana nos pacientes sem processos \n\ninfecciosos no momento da avalia\u00e7\u00e3o inicial. Connert e colaboradores \n\nencontraram associa\u00e7\u00e3o entre concentra\u00e7\u00f5es de PCT maiores de 0,58 \n\nng/ml (p &lt;0,001) e mortalidade no acompanhamento de dois meses.\n43\n\n \n\nUm estudo retrospectivo incluindo 202 cirr\u00f3ticos avaliou os n\u00edveis da \n\nPCR da admiss\u00e3o e n\u00e3o observou a sua rela\u00e7\u00e3o com a mortalidade em \n\n30 dias, no entanto a redu\u00e7\u00e3o desses n\u00edveis nos dias quatro ou cinco p\u00f3s-\n\nadmiss\u00e3o mostrou ter associa\u00e7\u00e3o com o aumento da sobrevida destes \n\npacientes\n50\n\n.  A cin\u00e9tica da PCT tamb\u00e9m foi avaliada em outros \n\nestudos.\n51,52 \n\nO decl\u00ednio das concentra\u00e7\u00f5es da PCT durante as primeiras \n\n72 horas no acompanhamento de pacientes criticamente enfermos \n\nmostrou ser um preditor de sobrevida mais eficaz do que as \n\nconcentra\u00e7\u00f5es iniciais.\n52\n\n Jensen e colaboradores encontraram resultados \n\nsemelhantes em pacientes internados em unidade de terapia intensiva.\n53\n\n \n\nAl\u00e9m das concentra\u00e7\u00f5es iniciais elevadas deste biomarcador, o aumento \n\nda PCT durante a interna\u00e7\u00e3o foram preditores independentes de \n\nmortalidade em 90 dias ap\u00f3s a admiss\u00e3o na unidade de terapia intensiva. \n\nDiante do exposto acima, parece que a cin\u00e9tica das concentra\u00e7\u00f5es de \n\nPCR e PCT durante o tratamento de infec\u00e7\u00e3o bacteriana \u00e9 \u00fatil em \n\npredizer o risco de mortalidade. No presente estudo, a avalia\u00e7\u00e3o da \n\ncin\u00e9tica da PCR e da PCT n\u00e3o foram realizadas, dessa maneira, n\u00e3o foi \n\nposs\u00edvel confirmar os dados apresentados pelos estudos descritos acima. \n\n  \n\n O presente estudo foi realizado em uma unidade de emerg\u00eancia, \n\nsendo que os dados dos pacientes que foram analisados simulam a \n\nsitua\u00e7\u00e3o real dos indiv\u00edduos infectados com cirrose hep\u00e1tica \n\ndescompensada. Al\u00e9m disso, os quadros infecciosos encontrados em \n\n\n\n42 \n\n \n\nalguns dos indiv\u00edduos no presente estudo proporcionaram valores de \n\npontos de corte mais fidedigno da PCR e da PCT para o diagn\u00f3stico de \n\ninfec\u00e7\u00e3o quando comparados aos pontos de corte encontrados por \n\nestudos realizados em unidades ambulatoriais. \n21- 22, 43 \n\n Algumas limita\u00e7\u00f5es do presente estudo merecem ser abordadas. \n\nO n\u00famero relativamente pequeno de pacientes e a inclus\u00e3o dos \n\nindiv\u00edduos que foram readmitidos devido \u00e0 descompensa\u00e7\u00e3o hep\u00e1tica \n\nap\u00f3s terem recebido alta hospitalar, podem permitir a ocorr\u00eancia de \n\nvieses de sele\u00e7\u00e3o, prejudicando a interpreta\u00e7\u00e3o dos resultados. No \n\nentanto, o n\u00famero de pacientes inclu\u00eddos na maioria dos estudos que \n\navaliaram marcadores inflamat\u00f3rios para o diagn\u00f3stico de infec\u00e7\u00e3o nos \n\npacientes portadores de cirrose hep\u00e1tica, foi semelhante ao n\u00famero da \n\nnossa amostra. Ainda assim, \u00e9 necess\u00e1ria valida\u00e7\u00e3o externa dos \n\nresultados aqui apresentados atrav\u00e9s de estudos prospectivos com maior \n\nn\u00famero de pacientes, especialmente no que diz respeito aos pontos de \n\ncorte dos marcadores de fase aguda. Outra limita\u00e7\u00e3o est\u00e1 no fato de que \n\ntrabalho foi realizado em uma unidade de emerg\u00eancia, sem \n\npadroniza\u00e7\u00e3o para o diagn\u00f3stico de infec\u00e7\u00e3o no momento da admiss\u00e3o \n\nhospitalar, o que pode ter proporcionado uma categoriza\u00e7\u00e3o equivocada \n\nentre os indiv\u00edduos do estudo. No entanto, a natureza prospectiva do \n\npresente estudo, com seguimento de todos os pacientes inclu\u00eddos \n\ndurante a admiss\u00e3o hospitalar e a an\u00e1lise do prontu\u00e1rio m\u00e9dico torna \n\nimprov\u00e1vel esse vi\u00e9s. \n\n Em conclus\u00e3o, a PCR e a PCT apresentaram boa acur\u00e1cia para o \n\ndiagn\u00f3stico de infec\u00e7\u00e3o bacteriana em pacientes cirr\u00f3ticos admitidos por \n\ncomplica\u00e7\u00f5es da doen\u00e7a. Pontos de corte mais elevados que aqueles \n\npreviamente sugeridos na literatura podem ser necess\u00e1rios, \n\nespecialmente no contexto de pacientes admitidos em servi\u00e7os de \n\nemerg\u00eancia nos quais quadros infecciosos mais graves e outras \n\ncomplica\u00e7\u00f5es cl\u00ednicas podem estar associados ao aumento substancial \n\ndos n\u00edveis de marcadores de fase aguda. A associa\u00e7\u00e3o entre maiores \n\nn\u00edveis de PCR e PCT e mortalidade a curto prazo sugerem potencial \n\ndestes biomarcadores como preditores progn\u00f3sticos nos portadores de \n\ncirrose hep\u00e1tica. \n\n \n\n \n\n \n\n \n\n \n\n\n\n43 \n\n \n\nREFER\u00caNCIAS \n\n \n\n1. Lefton, HB, Rosa  A, Cohen M. Diagnosis and epidemiology of \ncirrhosis. Med Clin N Am 2009;93:787-99. \n\n2. Iida VH, Silva TJA, Silva ASF, Silva LFF, Alves VAF. Hepatic \ncirrhosis: morphologic aspects related to its possible complications. A \n\nstudy focused on necropsies. J Bras Patol Med Lab 2005;41:29-36. \n\n3. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and \nprognostic indicators of survival in cirrhosis: a systematic review of 118 \n\nstudies. J Hepatol 2006;44:217-31. \n\n4. Fern\u00e1ndes J, Navasa M, G\u00f3mez J, Colmenero J, Vila J, Arroyo \nV et al. Bacterial infections in cirrhosis: epidemiological changes with \n\ninvasive procedures and norfloxacin prophylaxis. Hepatology 2002; \n\n35:140-48. \n\n5. Arvaniti V, D`Amico G , Fede G, Manousou P, Tsochatzis E, \nPleguezuelo M et al. Infections in patients with cirrhosis increase \n\nmortality four-fold and should be used in determining prognosis. \n\nGastroenterology 2010;139:1246-56. \n\n6. Garcia-Tsao G. Gut microflora in the pathogenesis of the \ncomplications of cirrhosis. Best Pract Res Clin Gastroenterol \n\n2004;18(2):353-72.  \n\n7. Fierer J, Finley F. Deficient serum bactericidal activity against \nEscherichia Coli in patients with cirrhosis of the liver. J Clin Invest \n\n1979;63:912-21. \n\n8. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal  N, \nThomsen AC et al. Acquired C3 deficiency in patients with alcoholic \n\ncirrhosis predisposes to infection and increased mortality. Gut \n\n1997;40:544-9. \n\n9. Code C, Kugler V, Bode JC. Endotoxemia in patients with \nalcoholic and non-alcoholic cirrhosis and in subjects with no evidence \n\nof chronic liver disease following acute alcohol excess. J Hepatol \n\n1987;4:8-14. \n\n10. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and \nmultiorgan failure in cirrhosis. Semin Liver Dis 2008;28(1):26-42. \n\n11. Wyke RJ. Problems of bacterial infection in patients with liver \ndisease. Gut 1987;28:623-41. \n\n\n\n44 \n\n \n\n12. Jin M, Khan  AI. Procalcitonin: uses in the clinical laboratory \nfor the diagnosis of sepsis. Lab Med 2010;41(3):173-77.  \n\n13. Liu K T, Lin TJ, Chan HM. Characteristics of febrile patients \nwith normal white blood cell counts and high C-reative protein levels in \n\nan emergency department. Kaohsiung J Med Sci 2008;24:248-53. \n\n14. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In \ncritically ill patients, serum procalcitonin is more useful in \n\ndifferentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit \n\nCare Res Pract 2011;2011:1-6. \n\n15. Pourakbari B, Mamishi S, Zafari J, KhairkhanH, Ashtiani MH, \nAbedini M et al. Evaluation of procalcitonin and neopterin level in \n\nserum of patients with acute bacterial infection. Braz J Infect Dis \n\n2010;14(3):252-5. \n\n16. Lipman J, Ho KM. An update on C-reactive protein for \nintensivists. Anaesth Intensive Care 2009; 37: 234-41.  \n\n17. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the \nsite of C-reactive protein formation. J Exp Med 1966;123:365-78. \n\n18. Le Moine O, Devi\u00e8re J, Devaster JM, Crusiaux A, Durand F, \nBernuau J et al. Interleukin-6: an early marker of bacterial infection in \n\ndecompensated cirrhosis. J Hepatol 1994;20:819-24. \n\n19. Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS et al. \nProduction of C-reactive protein in Escherichia coli-infected patients \n\nwith liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis \n\n2005;51:227-30.  \n\n20. Li CH, Yang RB, Pang JHS. Procalcitonin as a biomarker for \nbacterial infections in patients with liver cirrhosis in the emergency \n\ndepartment. Acad Emerg Med 2011;18:122-6. \n\n21. Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J \net al. Acute phase proteins in the diagnosis and prediction of cirrhosis \n\nassociated bacterial infections. Liver Int 2012;32(4):603-611. \n\n22. Tsiakalos A, Karatzaferis A, Ziakas P, Hatzis G. Acute-phase \nproteins as indicators of bacterial infection in patients with cirrhosis. \n\nLiver Int 2009;29(10):1538-42. \n\n23. Kretzschmar M, Kruger A, Schirrmeister W. Procalcitonin \nfollowing elective partial liver resection \u2013 origin from the liver?. Acta \n\nAnaesthesiol Scand 2001; 45: 1162\u20137. \n\n\n\n45 \n\n \n\n24. Meisner M, Muller V, Khakpour Z, Toegel E, Redl H. \nInduction of procalcitonina and proinflamatory cytokines in an \n\nanhepatic baboon endotoxin shock model. Shock 2003; 19(2):187-90. \n\n25. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum \nprocalcitonin and C-reactive protein levels as markers of bacterial \n\ninfection: a systematic review and meta-analysis. Clin Infect Dis \n\n2004;39:206-17. \n\n26. Geppert A, Steiner A, Delle-Karth G, Heinz G, Huber K. \nUsefulness of procalcitonin for diagnosing complicating sepsis in \n\npatients with cardiogenic shock. Intensive Care Med 2003;29:1384-9. \n\n27. Hatzistilianou M. Diagnostic and prognostic role of \nprocalcitonin in infections. ScientificWorldJournal 2010;10:1941-6. \n\n28. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC \ndefinitions for nosocomial infectious. Am J Infect Control 1988;16:128-\n\n40.  \n\n29. Runyon B A. Management of adult patients with ascites due to \ncirrhosis : an update. Hepatology 2004;49(6):2087-107.  \n\n30. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus \nWA, et al. Definitions for sepsis and organ failure and guidelines for the \n\nuse of innovative therapies in sepsis. The ACCP/SCCM Consensus \n\nConference Committee. American College of Chest Physicians/Society \n\nof Critical Care Medicine. Chest 1992;101:1644-55. \n\n31. Bajaj JA. Review article: the modern management of hepatic \nencephalopathy. Aliment Pharmacol Ther 2010;31:537-47. \n\n32. Angermayr B, Cejna M, Karnel F, Gschwantler  M, Koenig F, \nPidlichJ et al. Child-Pugh versus MELD score in predicting survival in \n\npatients undergoing transjugular intrahepatic portosystemic shunt. Gut \n\n2003(52):879-85.   \n\n33. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau \nTM, Kosberg CL et al. A Model to predict survival in patients with end-\n\nstage liver disease. Hepatology 2001;33:464-70.  \n\n34. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor \nfor sepsis and death. Chest 2003;114:1016-20. \n\n35. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-\nTsao G et al. Sepsis in cirrhosis: report on the 7\n\nth\n meeting of the \n\ninternational ascites club. Gut 2005;54:718-25. \n\n\n\n46 \n\n \n\n36. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, \nBissoli F et al. Bacterial infection in patients with advanced cirrhosis: a \n\nmulticentre prospective study. Dig Liver Dis 2001;33:41-8. \n\n37. Guarner C, Soriano G. Bacterial translocation and its \nconsequences in patients with cirrhosis.  Eur J Gastroenterol Hepatol \n\n2005; 17:27\u201331. \n\n38. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taur\u00e1 P, et al. \nBacterial translocation of enteric organisms in patients with cirrhosis J \n\nHepatol 2001;34(1):32-7. \n\n39. Albillos A, de la Hera A, Gonz\u00e1lez M, Moya JL, Calleja JL, \nMonserrat J et al. Increased lipopolysaccharide binding protein in \n\ncirrhotic patients with marked immune and hemodynamic derangement. \n\nHepatology 2003;37:208-1. \n\n40. Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Aubert G et \nal. Serum and ascitis procalcitonina levels in cirrhotic patients with \n\nspontaneous bacterial peritonitis:diagnostic value and relationship to \n\npro-inflamatory cytokines. Intensive Care Med 2000;26:1082-8. \n\n41. Bota DP, Van Nuffelen M, Zakariah AN, Vincebt JL et al. \nSerum levels of C-reactive protein and procalcitonin in critically ill \n\npatients with cirrhosis of the liver. J Lab Clin Med 2005;146:347-51. \n\n42. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et \nal. Procalcitonin increase after endotoxin injection in normal subjects. J \n\nClin Endocrinol Metab 1994;79:1605-8.  \n\n43. Connert S, Stremmel W, Elsing C. Procalcitonin is a valid \nmarker of infection in decompensated cirrhosis. Z Gastroenterol \n\n2003;41:165-70.  \n\n44. Elefsiniotis I S, Skounakis M, Vezali E, Pantazis KD, \nPetrocheilou A, Pirounaki M, et al. Clinical significance of serum \n\nprocalcitonin levels in patients with acute or chronic liver disease. Eur J \n\nGastroenterol Hepatol 2006;18:525-30. \n\n45. Schepis F, Bianchini M, Ferretti I, Marino M, Bonfreschi S, \nDattomo G et al. Procalcitonin is the best diagnostic and prognostic \n\nmarker of sepsis in decompensated cirrhotic patients. J Hepatol \n\n2010;52:S59-182. \n\n46. Gin\u00e8s P, Schrier RW. Renal failure in cirrhosis. N Engl J Med \n2009;361:1279-90. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Albillos%20A%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22de%20la%20Hera%20A%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Gonz%C3%A1lez%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Moya%20JL%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Calleja%20JL%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Monserrat%20J%22%5BAuthor%5D\n\n\n47 \n\n \n\n47. Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand \nM, Coriat P et al. Influence of renal dysfunction on the accuracy of \n\nprocalcitonin for the diagnosis of postoperative infection after vascular \n\nsurgery. Critical Care Medicine 2008;36(4):1147-54.  \n\n48. Navasa M, Follo A, Filella X, Jim\u00e9nez W, Francitorra A, Planas \nR et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial \n\nperitonitis in cirrhosis: relationship with the development of renal \n\nimpairment and mortality. Hepatology 1998;27(5):1227-32. \n\n49. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, \nBissoli F et al. Bacterial infection in patients with advanced cirrhosis: a \n\nmulticentre prospective study. Dig Liver Dis 2001;33:41-8. \n\n50. Ha YE, Kang CI, Joo EJ, Joung MK, Chung DR, Peck KR et al. \nUsefulness of C-reactive protein for evaluating clinical outcomes in \n\ncirrhotic patients with bacteremia. Korean J Intern Med 2011;26(2):195-\n\n200. \n\n51. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, et al. \nProcalcitonin kinetics within the first days of sepsis: relationship with \n\nthe appropriateness of antibiotic therapy and the outcome. Crit Care \n\n2009;13(2):R38.  \n\n52. Karlsson S, Heikkinen M, Pettil\u00e4 V, Alila S, V\u00e4is\u00e4nen S, Pulkki \nK, et al. Predictive value of procalcitonin decrease in patients with \n\nsevere sepsis: a prospective observational study. Crit Care \n\n2010;14(6):R205. \n\n53. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, \nTvede M. Procalcitonin increase in early identification of critically ill \n\npatients at high risk of mortality. Crit Care Med 2006;34(10):2596-602. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Birenbaum%20A%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Langeron%20O%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Le%20Manach%20Y%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bertrand%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bertrand%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Coriat%20P%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Navasa%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Follo%20A%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Filella%20X%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Jim%C3%A9nez%20W%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Francitorra%20A%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Planas%20R%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Planas%20R%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Borzio%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Salerno%20F%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Piantoni%20L%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Cazzaniga%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Angeli%20P%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bissoli%20F%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ha%20YE%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kang%20CI%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Joo%20EJ%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Joung%20MK%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Chung%20DR%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Peck%20KR%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Charles%20PE%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Tinel%20C%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Barbar%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Aho%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Prin%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Doise%20JM%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Karlsson%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Heikkinen%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Pettil%C3%A4%20V%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Alila%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22V%C3%A4is%C3%A4nen%20S%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Pulkki%20K%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Pulkki%20K%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Jensen%20JU%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Heslet%20L%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Jensen%20TH%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Espersen%20K%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Steffensen%20P%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Tvede%20M%22%5BAuthor%5D\n\n\n48 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n49 \n\n \n\nANEXOS \n \n\nANEXO A - Certificado de aprova\u00e7\u00e3o do Comit\u00ea de \u00c9tica em Pesquisa \n\ncom Seres Humanos (CEPSH). \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n\n\n50 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n51 \n\n \n\nANEXO B - Crit\u00e9rios diagn\u00f3sticos de infec\u00e7\u00e3o conforme o \u201cCenter for \n\nDiseases Control\u201d  \n\n \n\nAs defini\u00e7\u00f5es s\u00e3o baseadas em v\u00e1rios princ\u00edpios importantes. A \n\ninforma\u00e7\u00e3o utilizada para determinar a presen\u00e7a de uma infec\u00e7\u00e3o \n\nenvolve v\u00e1rias combina\u00e7\u00f5es de achados cl\u00ednicos e resultados \n\nlaboratoriais. A evid\u00eancia cl\u00ednica \u00e9 baseada na observa\u00e7\u00e3o direta do \n\npaciente ou na revis\u00e3o do prontu\u00e1rio do mesmo. Evid\u00eancia laboratorial \n\nde infec\u00e7\u00e3o leva em conta os resultados das culturas, teste com ant\u00edgeno \n\ne detec\u00e7\u00e3o de anticorpos ou visualiza\u00e7\u00e3o microsc\u00f3pica do \n\nmicroorganismo. Outros dados complementares relevantes s\u00e3o os \n\nm\u00e9todos diagn\u00f3sticos de imagem, como a radiografia, exame \n\nultrassonogr\u00e1fico, tomografia computadorizada e resson\u00e2ncia \n\nmagn\u00e9tica, al\u00e9m dos procedimentos endosc\u00f3picos, bi\u00f3psias e pun\u00e7\u00e3o \n\naspirativa por agulha. \n\nPneumonia: utilizar qualquer um dos dois crit\u00e9rios: \n\n 1 -  estertora\u00e7\u00e3o ou macicez \u00e0 percuss\u00e3o no exame f\u00edsico do \n\nt\u00f3rax associado \u00e0 qualquer um desses achados: in\u00edcio de escarro \n\npurulento ou mudan\u00e7a na sua caracter\u00edstica; microorganismo isolado na \n\nhemocultura; isolamento de pat\u00f3geno obtido atrav\u00e9s do aspirado \n\nendotraqueal, escovado br\u00f4nquico ou bi\u00f3psias \n\n 2 -  radiografia de t\u00f3rax mostrando novo infiltrado, cavita\u00e7\u00e3o ou \n\nefus\u00e3o pleural associado \u00e0 qualquer um desse achados: in\u00edcio de escarro \n\npurulento ou mudan\u00e7a na sua caracter\u00edstica; microorganismo isolado na \n\nhemocultura; isolamento de pat\u00f3geno obtido atrav\u00e9s do aspirado \n\nendotraqueal, escovado br\u00f4nquico ou bi\u00f3psias; isolamento de v\u00edrus ou \n\ndetec\u00e7\u00e3o de ant\u00edgeno viral na secre\u00e7\u00e3o respirat\u00f3ria; surgimento de IgM \n\nou aumento de 4 vezes nos t\u00edtulos s\u00e9ricos de IgG para pat\u00f3genos \n\nespec\u00edficos; evid\u00eancia histopatol\u00f3gica de pneumonia. \n\nInfec\u00e7\u00e3o do trato urin\u00e1rio: utilizar qualque um dos dois \n\ncrit\u00e9rios: \n\n 1 - um desses achados sem causa conhecida: febre > 38\no\n C, \n\nurg\u00eancia, polaci\u00faria, dis\u00faria ou dor suprap\u00fabica associado \u00e0 cultura de \n\nurina com ? 10\n5\n UFC/ml com duas ou menos esp\u00e9cies de \n\nmicroorganismos. \n\n 2 - dois dos seguintes achados: febre > 38\no\n C, urg\u00eancia, \n\npolaci\u00faria, dis\u00faria ou dor suprap\u00fabica associado \u00e0 qualquer uma dessas \n\napresenta\u00e7\u00f5es: esterase leucocit\u00e1ria ou nitrito positivo; pi\u00faria (? 10 \n\nleuc\u00f3citos/mm\n3\n ou ? 3 leuc\u00f3citos por campo de grande aumento); \n\n\n\n52 \n\n \n\nvisualiza\u00e7\u00e3o de microorganismos na urina pela colora\u00e7\u00e3o de Gram; 2 \n\nculturas de urina positivas para o mesmo microorganismo (Gram \n\nnegativa ou Staphylococcus saprophyticus) com ? 10\n2\n UFC/ml; \n\nurocultura com pat\u00f3geno \u00fanico com ? 10\n5\n UFC/ml em pacientes sendo \n\ntratados com antimicrobianos adequados; diagn\u00f3stico m\u00e9dico pr\u00e9vio de \n\ninfec\u00e7\u00e3o. \n\nInfec\u00e7\u00e3o de pele: utilizar qualquer um dos dois crit\u00e9rios: \n\n1 -  drenagem purulenta, p\u00fastulas, ves\u00edculas ou bolhas no local \n\nafetado. \n\n2 \u2013 dois dos seguintes achados: dor localizada, edema, rubor ou \n\ncalor associados \u00e0 qualquer um dos seguintes: organismo isolado ap\u00f3s \n\naspira\u00e7\u00e3o ou drenagem da secre\u00e7\u00e3o local (se o organismo for da flora \n\nnormal da pele, a cultura deve conter um \u00fanico germe); hemocultura \n\npositiva; teste de ant\u00edgeno positivo no sangue ou no tecido afetado; \n\nvisualiza\u00e7\u00e3o de c\u00e9lulas gigantes multinucleadas no tecido afetado \n\natrav\u00e9s do exame microsc\u00f3pico; surgimento de IgM ou aumento em 4 \n\nvezes nos t\u00edtulos de IgG para pat\u00f3genos espec\u00edficos.  \n\n Gastroenterite: utilizar qualquer um dos dois crit\u00e9rios: \n\n 1 \u2013 diarr\u00e9ia de in\u00edcio agudo (consist\u00eancia l\u00edquida por mais de 12 \n\nhoras) com ou sem v\u00f4mitos ou febre (> 38\no\n C) e nenhuma causa n\u00e3o \n\ninfecciosa \n\n 2 \u2013 dois dos seguintes achados com nenhuma causa \n\nestabelecida: n\u00e1useas, v\u00f4mitos, dor abdominal ou cefal\u00e9ia e qualquer um \n\ndos seguintes: pat\u00f3geno ent\u00e9rico isolado em cultura de fezes ou swab \n\nretal; pat\u00f3geno ent\u00e9rico detectado em exame microsc\u00f3pico; detec\u00e7\u00e3o \n\natrav\u00e9s de teste com ant\u00edgeno ou detec\u00e7\u00e3o de anticorpos nas fezes ou \n\nsangue; pesquisa de toxina positivo; surgimento de IgM ou aumento em \n\n4 vezes nos t\u00edtulos de IgG para pat\u00f3genos espec\u00edficos.   \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n53 \n\n \n\nANEXO C - Conceitos e defini\u00e7\u00f5es da \u201cAmerican College of Chest              \n\nPhysicians/Society of Critical Care Medicine\u201d \n\n \n\nOs conceitos descritos a seguir foram estabelecidos de acordo \n\ncom a defini\u00e7\u00e3o da \u201cAmerican College of Chest Physicians/Society Of \n\nCritical Care Medicine\u201d (ACCP/SCCM) e baseados no Comit\u00ea da \n\nConfer\u00eancia de Consenso de 1992. \n\nInfec\u00e7\u00e3o: fen\u00f4meno patol\u00f3gico caracterizado por uma resposta \n\ninflamat\u00f3ria \u00e0 presen\u00e7a de microorganismos ou \u00e0 invas\u00e3o de tecido \n\nnormalmente est\u00e9ril do hospedeiro por germes patog\u00eanicos. \n\nBacteremia: presen\u00e7a de bact\u00e9ria vi\u00e1vel no sangue. V\u00edrus, \n\nfungos, parasitas, e outros pat\u00f3genos no sangue devem ser descritos de \n\numa maneira similar (viremia, fungemia, parasitemia). \n\nS\u00edndrome da resposta inflamat\u00f3ria sist\u00eamica (SIRS): resposta \n\ninflamat\u00f3ria sist\u00eamica a uma variedade de insultos cl\u00ednicos graves. Esta \n\nresposta pode ocorrer na aus\u00eancia de infec\u00e7\u00e3o, como por exemplo, em \n\npacientes com traumatismos, queimaduras e pancreatites.  \n\nClinicamente a SIRS \u00e9 manifestada por duas ou mais das \n\nseguintes condi\u00e7\u00f5es: \n\n- Temperatura axilar > 38\no\n C ou &lt;36\n\no\n C \n\n- Frequ\u00eancia card\u00edaca > 90 bpm \n\n- Frequ\u00eancia respirat\u00f3ria > 20 mpm ou PCO2 &lt;32 mmHg \n\n- Contagem de leuc\u00f3citos > 12.000 c\u00e9lulas/mm\n3\n, &lt;400 \n\nc\u00e9lulas/mm\n3\n, ou > 10% de formas jovens  \n\n Sepse: resposta sist\u00eamica \u00e0 infec\u00e7\u00e3o que se manifesta atrav\u00e9s \n\ndos crit\u00e9rios da SIRS. \n\n Sepse grave: sepse associada com disfun\u00e7\u00e3o org\u00e2nica, \n\nhipoperfus\u00e3o ou hipotens\u00e3o. Hipoperfus\u00e3o e anormalidades perfusionais \n\nque podem incluir, mas n\u00e3o s\u00e3o limitadas \u00e0 acidose l\u00e1ctica, olig\u00faria ou \n\naltera\u00e7\u00e3o aguda do estado mental. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n54 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n55 \n\n \n\nANEXO D \u2013 Gradua\u00e7\u00e3o da encefalopatia hep\u00e1tica conforme os crit\u00e9rios \n\nde West-Haven \n\n \n\nEst\u00e1gio Crit\u00e9rios de West Haven \n\n0 Nenhuma anormalidade detectada \n\n1 \n\nFalta de aten\u00e7\u00e3o leve \n\nEuforia ou ansiedade \n\nDiminui\u00e7\u00e3o do tempo de aten\u00e7\u00e3o \n\nDesempenho de adi\u00e7\u00e3o prejudicado \n\n2 \n\nLetargia ou apatia \n\nDesorienta\u00e7\u00e3o leve no tempo e espa\u00e7o \n\nMudan\u00e7as s\u00fabitas de personalidade e \n\ncomportamento inadequado \n\nDesempenho de subtra\u00e7\u00e3o prejudicado \n\n3 \n\nSonol\u00eancia mais importante, por\u00e9m responsiva \n\naos est\u00edmulos verbais \n\nImportante confus\u00e3o e desorienta\u00e7\u00e3o \n\n4 Coma \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n56 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n57 \n\n \n\nANEXO E \u2013 Classifica\u00e7\u00e3o de Child-Pugh \n\n \n\nCrit\u00e9rio 1 ponto 2 pontos 3 pontos \n\nBilirrubina \n\ntotal (mg/dl) \n<2 2-3 >3 \n\nAlbumina \n\ns\u00e9rica (g/dl) \n>3,5 2,8-3,5&lt;2,8 \n\nRNI&lt;1,7 1,71-2,20 >2,20 \n\nAscite Nenhuma Leve Intensa \n\nEncefalopatia \n\nhep\u00e1tica \nNenhuma \n\nGrau I-II (ou \n\nsuprimida \n\ncom medica\u00e7\u00e3o) \n\nGrau III-IV \n\n(ou refrat\u00e1ria) \n\n \nInterpreta\u00e7\u00e3o: \n\nClasse A = 5 a 6 pontos \n\nClasse B = 7 a 9 pontos \n\nClasse C = 10 a 15 pontos \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nhttp://pt.wikipedia.org/wiki/Bilirrubina\nhttp://pt.wikipedia.org/wiki/Bilirrubina\nhttp://pt.wikipedia.org/wiki/Albumina\nhttp://pt.wikipedia.org/wiki/Albumina\nhttp://pt.wikipedia.org/wiki/Ascite\nhttp://pt.wikipedia.org/wiki/Encefalopatia_hep%C3%A1tica\nhttp://pt.wikipedia.org/wiki/Encefalopatia_hep%C3%A1tica\n\n\n58 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n59 \n\n \n\nANEXO F \u2013 F\u00f3rmula matem\u00e1tica para o c\u00e1lculo do modelo MELD \n\n(Model for End-Stage Liver Disease) \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nMELD (Model for End-Stage Liver Disease) = \n \n\n10 x (0,957 Log creatinina [mg/dl] + 0,378 Log  \n \n \n \n \n \n \n \n \n \n\n \n\n\n\n60 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n61 \n\n \n\nAP\u00caNDICES \n \n\nAP\u00caNDICE A - Termo de Consentimento Livre e Esclarecido (TCLE) \n\n \n\nTERMO DE CONSENTIMENTO LIVRE E \n\nESCLARECIDO \n\nAVALIA\u00c7\u00c3O DE MARCADORES PROGN\u00d3STICOS EM \n\nPORTADORES DE CIRROSE HEP\u00c1TICA DESCOMPENSADA \nVoc\u00ea est\u00e1 sendo convidado para participar de um projeto de \n\npesquisa: Avalia\u00e7\u00e3o de marcadores progn\u00f3sticos em portadores de \n\ncirrose hep\u00e1tica descompensada. Este projeto tem o objetivo de \nidentificar dados da avalia\u00e7\u00e3o m\u00e9dica ou de exames laboratoriais que \n\npossam nos ajudar a identificar os pacientes com doen\u00e7a mais grave. Os \n\nresultados desta pesquisa poder\u00e3o permitir a cria\u00e7\u00e3o de ferramentas para \n\na identifica\u00e7\u00e3o r\u00e1pida dos pacientes com doen\u00e7a mais grave, permitindo \n\nassim um tratamento mais adequado. \n\nCaso voc\u00ea concorde em participar deste estudo, ser\u00e1 feita uma \n\navalia\u00e7\u00e3o cl\u00ednica (entrevista e exame f\u00edsico) no primeiro dia da sua \n\ninterna\u00e7\u00e3o e 48 horas depois.  Al\u00e9m disso, uma coleta de sangue ser\u00e1 \n\nrealizada por pun\u00e7\u00e3o perif\u00e9rica na veia do antebra\u00e7o tamb\u00e9m nestes dois \n\nmomentos. Parte do material ser\u00e1 destinada aos exames de rotina (que \n\ns\u00e3o necess\u00e1rios para avalia\u00e7\u00e3o do seu caso durante a interna\u00e7\u00e3o) e uma \n\noutra por\u00e7\u00e3o ser\u00e1 armazenadas em freezer a -80\u00ba C para a posterior \n\ndosagem dos exames referentes a este estudo, que s\u00e3o: Anti-HEV IgG, \n\nprocalcitonina, GST-?, neoep\u00edtopos da CK-18 e queratina 18 sol\u00favel. \n\n N\u00e3o existem riscos importantes relacionados a tal procedimento, \n\npodendo ocorrer, como consequ\u00eancia da coleta de sangue, dor no local \n\nda pun\u00e7\u00e3o e/ou forma\u00e7\u00e3o de hematoma local. \n\nN\u00e3o h\u00e1 benef\u00edcio direto para o participante. Em qualquer etapa do \n\nestudo, voc\u00ea ter\u00e1 acesso aos profissionais respons\u00e1veis pela pesquisa \n\npara esclarecimento de eventuais d\u00favidas. Os principais investigadores \n\nenvolvidos s\u00e3o o Dr. Marcelo Ronsoni, o Dr. Cesar Lazzarotto e o Dr. \n\nLeonardo de Lucca Schiavon que podem ser encontrados no endere\u00e7o: \n\nDepartamento de Cl\u00ednica M\u00e9dica, Hospital Universit\u00e1rio/Campus \n\nUniversit\u00e1rio \u2013 Trindade - Cep 88040-970 - Florian\u00f3polis \u2013 SC Fone \n\n(48) 37219149/37219014; e-mail: cesarlazzarotto@ig.com.br ou \n\nmarceloronsoni@terra.com.br. Se voc\u00ea tiver alguma considera\u00e7\u00e3o ou \n\nd\u00favida sobre a \u00e9tica da pesquisa, entre em contato com o Comit\u00ea de \n\n\u00c9tica em Pesquisa (CEP): Universidade Federal de Santa Catarina; Pr\u00f3-\n\nmailto:cesarlazzarotto@ig.com.br\n\n\n62 \n\n \n\nReitoria de Pesquisa e Extens\u00e3o - Campus Universit\u00e1rio - Trindade - \n\nFlorian\u00f3polis/SC; Tel: (48) 3721-9206. \n\n\u00c9 garantida a liberdade da retirada de consentimento a qualquer \n\nmomento e deixar de participar do estudo, sem qualquer preju\u00edzo \u00e0 \n\ncontinuidade de seu tratamento na Institui\u00e7\u00e3o. \n\nAs informa\u00e7\u00f5es obtidas ser\u00e3o analisadas em conjunto com outros \n\npacientes, n\u00e3o sendo divulgada a identifica\u00e7\u00e3o de nenhum paciente. \n\nVoc\u00ea tem o direito de ser mantido atualizado sobre os resultados \n\nparciais das pesquisas, assim que os mesmos forem de conhecimento \n\ndos pesquisadores. \n\nN\u00e3o h\u00e1 despesas pessoais para o participante em qualquer fase do \n\nestudo, incluindo exames e consultas. Tamb\u00e9m n\u00e3o h\u00e1 compensa\u00e7\u00e3o \n\nfinanceira relacionada \u00e0 sua participa\u00e7\u00e3o. Se existir qualquer despesa \n\nadicional, ela ser\u00e1 absorvida pelo or\u00e7amento da pesquisa. \n\nEm caso de dano pessoal, diretamente causado pelos \n\nprocedimentos propostos neste estudo (nexo causal comprovado), o \n\nparticipante tem direito a tratamento m\u00e9dico na Institui\u00e7\u00e3o, bem como \n\n\u00e0s indeniza\u00e7\u00f5es legalmente estabelecidas. \n\nSegue abaixo os termos da declara\u00e7\u00e3o para poder participar \n\ndo estudo: \n\nAcredito ter sido suficientemente informado a respeito do estudo \n\n\u201cAvalia\u00e7\u00e3o de marcadores progn\u00f3sticos em portadores de cirrose \n\nhep\u00e1tica descompensada\u201d. \n\nEu discuti com os pesquisadores respons\u00e1veis sobre a minha \n\ndecis\u00e3o em participar nesse estudo. Ficaram claros para mim quais s\u00e3o \n\nos prop\u00f3sitos do estudo, os procedimentos a serem realizados, seus \n\ndesconfortos e riscos, as garantias de confidencialidade e de \n\nesclarecimentos permanentes. Ficou claro tamb\u00e9m que minha \n\nparticipa\u00e7\u00e3o \u00e9 isenta de despesas e que tenho garantia do acesso a \n\ntratamento hospitalar, caso seja necess\u00e1rio. Concordo voluntariamente \n\nem participar deste estudo e poderei retirar o meu consentimento a \n\nqualquer momento: antes ou durante o mesmo, sem penalidades, \n\npreju\u00edzo, perda de qualquer benef\u00edcio que eu possa ter adquirido, ou no \n\nmeu atendimento neste Servi\u00e7o. \n\n \n\n \n\nNome do participante Assinatura Data \n\nOu \n\n\n\n63 \n\n \n\n \n\nRespons\u00e1vel legal  Assinatura  Data \n\n \n\n \n\n_________________________________________________ \n\nRespons\u00e1vel pelo estudo Assinatura  Data \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n64 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n65 \n\n \n\nAP\u00caNDICE B - Question\u00e1rio de avalia\u00e7\u00e3o dos cirr\u00f3ticos \n\ndescompensados na admiss\u00e3o hospitalar  \n\n \n\nAVALIA\u00c7\u00c3O DE MARCADORES PROGN\u00d3STICOS EM \n\nPORTADORES DE CIRROSE HEP\u00c1TICA DESCOMPENSADA \n\nFicha admiss\u00e3o \n\n \nDados identifica\u00e7\u00e3o: \n\nNome: Num Emerg: \n\nData interna\u00e7\u00e3o: \n\n______/_____/______ hora: \nData avalia\u00e7\u00e3o: ___/___/___  hora:_____ \n\nRegistro: Nasc: ___/___/___ \n\nSexo: \n? M  ? \n\nF \n\nRa\u00e7a: ? Br  ? Negr \n\n  ? Pard  ? Asia  ? Verm \n\nTelefone1:  (____) __________ Telefone2: (____) ______ \n\nProfiss\u00e3o: \nEstado civil: ? Solt ? Casado  \n\n? Divorciado ? Amaziado ? Vi\u00favo  \n\n \n\nDados da doen\u00e7a de base: \n\nCausa da cirrose: ? HBV ? HCV ? \u00c1lcool ? HAI ? CBP ? CEP  \n\n? Hemocr ? NASH ? Criptog\u00eanica ? Outra:_____________________ \n\nJ\u00e1 fez bi\u00f3psia: ? N\u00e3o ? Sim -> \n\nOnde______________Ano_________ \n\nPaciente da gastro HU: ? N\u00e3o  \n\n ? Sim -> M\u00e9dico \n\nDiagn\u00f3stico da cirrose (hipertens\u00e3o portal = varizes es\u00f4fago/g\u00e1stricas \n\nou ascite com GASA ? 1,1 ou USG Doppler sugestivo): \n? Bi\u00f3psia ? Hipertens\u00e3o portal + exame imagem ? Hipertens\u00e3o portal + \n\nestigmas cl\u00ednicos ? Hipertens\u00e3o portal + laborat\u00f3rio ? \n\nOutro_______________________ \n\nDescompensa\u00e7\u00f5es anteriores: ? N\u00e3o  ? \n\nAscite ? HDA ? Encefalopatia \n\nData primeira \n\ndescompensa\u00e7\u00e3o (m\u00eas e ano): \n\n_____/________ \n\n \n\n \n\n \n\n \n\n \n\n\n\n66 \n\n \n\nAntecedentes: \n\nComorbidades: ? DM     ? HAS     ? HIV    ? Pneumo:_____________ \n\n? Cardio:________________ ? Gastro:______________ ? Nefro:______    \n\n? Endocrino:_____________ ? Reumato:____________ ? \n\nPsiquiatria:__________ ? Infecto: __________________? Outras_____ \n\nMedica\u00e7\u00f5es: ? Propranolol _____mg/d  ? Espironolactona ______mg/d \n\n  ? Furosemida ______mg/d ? Lactulose _______mL/d    ? Outras: ____ \n\nCirurgias: ? N\u00e3o  ? Sim  Quais/a________________ \n\nTabagismo: ? N\u00e3o  ? Sim -> \n\nAnos/ma\u00e7o____ \n\nEtilismo atual: ? N\u00e3o  ? Sim __g/dia \n\nEtilismo pr\u00e9vio: ? N\u00e3o  \n\n ? Sim ___g/dia   Ano  in\u00edcio:______ \n\nAno final:_______ \n\nUso drogas atual: ? N\u00e3o  ? Sim -> quais ?_________________________ \n\nUso drogas pr\u00e9vio: ? N\u00e3o  ? Sim -> quais ?________________________ \n\n \n\nDescompensa\u00e7\u00e3o atual: \n\nMotivo interna\u00e7\u00e3o: ? Descompensa\u00e7\u00e3o da cirrose ? Realiza\u00e7\u00e3o de \n\nexame  \n\n? Outro______________________________________________ \n\nDescompensa\u00e7\u00f5es atuais(marcar mais de uma s/n): ? ascite ? \n\nPBE ? encefalopatia ? HDA ? SHR ? icter\u00edcia \n\nIn\u00edcio dos sintomas (que motivaram interna\u00e7\u00e3o): \n______/______/______ \n\n \n\nDados exame f\u00edsico (exame f\u00edsico realizado pelo PESQUISADOR) \n\nPeso: Altura: PAS:  PAD:  FC: FR: SatO2 e FiO2: \n\nTemperatura: \no\nC  \n\nFebre: ? N\u00e3o  \n\n ? Sim \nHipotens\u00e3o: ? N\u00e3o  ? Sim \n\nIcter\u00edcia: \n ? N\u00e3o  ? \n\nSim \n\nEritema palmar:  \n\n? N\u00e3o  ? Sim \nTelangiectasias: \n\n ? N\u00e3o  ? Sim \nGinecomastia:  \n\n? N\u00e3o  ? Sim \n\n \n\n \n\n\n\n67 \n\n \n\nAscite (preencher se ASCITE presente) \n\nIn\u00edcio do aumento volume abdominal: ______/______/______ \n\nGradua\u00e7\u00e3o: ? Ausente ? Grau 1 (apenas USG) ? Grau 2 (moderada \n\nn\u00e3o tensa) ? Grau 3 (ascite importante/tensa) \n\nParacentese: ? N\u00e3o  ? Sim -> Dia ______/______/______  \n\nVolume:___________ \n\n \n\nHemorragia digestiva alta (preencher se paciente com HDA) \n\nIn\u00edcio dos \n\nsintomas: \n\n__/__/___/ \n\nHemat\u00eamese:  \n? N\u00e3o  ? Sim \n\nMelena:  \n? N\u00e3o  ? Sim \n\nEpis\u00f3dios ant:  \n? N\u00e3o  ? Sim \n\nInstabilidade \n\nhemodin\u00e2mica: ? N\u00e3o  \n\n? Sim  \n\nTransfus\u00e3o: ? N\u00e3o  ? Sim -> \n\n______Unidades Concentrado Hem\u00e1ceas \n\nEDA: ? N\u00e3o  ? Sim -> Fonte sangramento: ? Varizes es\u00f4fago ? \n\nVarizes g\u00e1stricas ? Gastropatia ? \u00dalcera g\u00e1strica ? \u00dalcera duodenal  \n\n? outra___________________________________________ \n\nTratamento endosc\u00f3pico: ? N\u00e3o  ? Sim -> ? Escleroterapia ? \n\nLigadura el\u00e1stica ? Cianocrilato ? outro_________________________ \n\n \n\nEncefalopatia hep\u00e1tica (preencher para TODOS) \n\nCrit\u00e9rios de West Haven: \n\n? 0 ? 1 ? 2 ? 3 ? 4 \n\nGlasgow:  AO_____  RV____  RM_____  \n\nTotal:__________ \n\nFator precipitante: ? Desconhecido ? HDA ? Infec\u00e7\u00e3o \n\ns\u00edtio______________ ? Constipa\u00e7\u00e3o ? Dist\u00farbio hidroeletrol\u00edtico ? \n\nBenzodiazep\u00ednicos ? Diur\u00e9ticos ? \n\nOutra_________________________________________________ \n\n \n\nInfec\u00e7\u00e3o (preencher para TODOS na admiss\u00e3o) \n\nInfec\u00e7\u00e3o \n\npresente:  \n\n? N\u00e3o  ? Sim \n\nTipo infec\u00e7\u00e3o: ? PBE ? ITU ? Pneumonia ? Pele \n\n? outro________________________________ \n\nConfirmado com exame \nlaboratorial: ? N\u00e3o  ? \n\nSim \n\nConfirmado com cultura: ? N\u00e3o  ? Sim -> \n\nGerme_________________________ \n\n \n\n \n\n\n\n68 \n\n \n\nPrescri\u00e7\u00e3o atual (medicamentos J\u00c1 INICIADOS no momento da avalia \n\nOctreotide: ? N\u00e3o  ? Sim -> \n\nDose \n\nAntibi\u00f3tico: ? N\u00e3o  ? Sim  \n\nQual___________Dose______ \n\nEspironolactona: ? N\u00e3o  ? Sim  \n\n \n\nFurosemida: ? N\u00e3o  ? Sim  \n\nDose \n\nLactulose: ? N\u00e3o  ? Sim   \nMetronidazol: ? N\u00e3o  ? Sim -> \n\nDose__________________ \n\nNeomicina: ? N\u00e3o  ? Sim \nTotal volume \n\n(cristal\u00f3ides/col\u00f3ides) at\u00e9 o \nmomento: _______ mL \n\nOutras: \n\n \n\nLaborat\u00f3rio (apenas exames ADMISS\u00c3O) \n\nSANGUE \n\nHb: Ht: Leuco: Formas jovens (n): Neutr (n) : \n\nLinf\u00f3citos (n): \nMon\u00f3citos \n\n(n): \n\nEosinof \n\n(n): \n\nBasof \n\n(n): \nPlaquetas: \n\nNa: K: Ur: Cr: TP: \n\nAP: RNI: \nTTPA \n\n(seg): \n\nTTPA \n\n(rel): \nAlbumina: \n\nGlicemia: Insulina: TSH: T3: T4L: \n\nPCR: Lactato: AST: ALT: GGT: \n\nFA: BT: BD: IGF-I: IGFBP3: \n\nProcalcitonina\n\n: \n    \n\n \n\nL\u00cdQUIDO ASC\u00cdTICO \n\nPT: Alb: pH: DHL: Gli: \n\n\n\n69 \n\n \n\nADA: \nCitol \n\ntotal: \nHem: PMN: Linfo/mono: \n\nURINA \n\npH: Leuco: Hem:   \n\nAVALIA\u00c7\u00c3O DE MARCADORES PROGN\u00d3STICOS EM \n\nPORTADORES DE CIRROSE HEP\u00c1TICA DESCOMPENSADA \n\nFicha 7 dias \n\n \n\nDados identifica\u00e7\u00e3o: \n\nNome: Num Emerg: \n\nData interna\u00e7\u00e3o: \n\n______/_____/_____hora:___\n\n__________ \n\nData avalia\u00e7\u00e3o: \n\n______/_____/______hora:_______\n\n________ \n\n \n\nDados da interna\u00e7\u00e3o: \n\nAinda internado: ? N\u00e3o  ? Sim  \n\n? \u00d3bito \n\nSe \u00f3bito:  \n\nData do \u00f3bito_______ \n\nCausa do \u00f3bito _____ \n\n \n\nPREENCHER ABAIXO PARA OS PACIENTES QUE AINDA \n\nEST\u00c3O INTERNADOS \nAscite (preencher se ASCITE presente) \n\nGradua\u00e7\u00e3o: ? Ausente ? Grau 1 (apenas USG) ? Grau 2 \n\n(moderada n\u00e3o tensa) ? Grau 3 (ascite importante/tensa) \n\nParacentese: ? N\u00e3o  ? Sim -> Dia ______/______/______  \n\nVolume:___________ \n\n \n\nHemorragia digestiva alta (preencher se paciente com HDA) \n\nIn\u00edcio dos \n\nsintomas: \n___/___/___ \n\nHemat\u00eamese:  \n? N\u00e3o  ? Sim \n\nMelena:  \n? N\u00e3o  ? Sim \n\nEpis\u00f3dios ant: \n? N\u00e3o  ? Sim \n\nInstabilidade \n\nhemodin\u00e2mica: \n? N\u00e3o  ? Sim  \n\nTransfus\u00e3o: ? N\u00e3o  ? Sim  \n\n __Unidades Concentrado Hem\u00e1ceas \n\nEDA: ? N\u00e3o  ? Sim -> Fonte sangramento: ? Varizes es\u00f4fago ? \n\n\n\n70 \n\n \n\nVarizes g\u00e1stricas ? Gastropatia ? \u00dalcera g\u00e1strica ? \u00dalcera duodenal \n\n? outra_______ \n\nTratamento endosc\u00f3pico: ? N\u00e3o  ? Sim -> ? Escleroterapia ? \n\nLigadura el\u00e1stica \n\n ? Cianocrilato ? outro_ \n\n \n\n \n\n \n\nEncefalopatia hep\u00e1tica (preencher para TODOS) \n\nCrit\u00e9rios de West Haven: ? 0 ? 1 ? 2 \n\n? 3 ? 4 \n\nGlasgow:  AO_____  \n\nRV____  RM_____  \n\nTotal:___ \n\nFator precipitante: ? Desconhecido ? HDA ? Infec\u00e7\u00e3o s\u00edtio_____ \n\n? Constipa\u00e7\u00e3o \n\n ? Dist\u00farbio hidroeletrol\u00edtico ? Benzodiazep\u00ednicos ? Diur\u00e9ticos \n\n? Outra______ \n\n \n\nInfec\u00e7\u00e3o (preencher para TODOS) \n\nInfec\u00e7\u00e3o presente: \n? N\u00e3o  ? Sim \n\nTipo infec\u00e7\u00e3o: ? PBE ? ITU ? Pneumonia ? \n\nPele ? outro \n\nConfirmado com exame \n\nlaboratorial: ? N\u00e3o  ? Sim \n\nConfirmado com cultura: ? N\u00e3o  \n\n ? Sim Germe __________________ \n\nAntibi\u00f3tico: ? N\u00e3o  ? Sim Qual:_____________  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n71 \n\n \n\nAP\u00caNDICE C - Artigo Cient\u00edfico (Vers\u00e3o L\u00edngua Inglesa) \n\n \n\nManuscript title: \nACUTE PHASE PROTEINS FOR THE DIAGNOSIS OF \n\nBACTERIAL INFECTION AND PREDICTION OF MORTALITY IN \n\nACUTE COMPLICATIONS OF CIRRHOSIS \n\n \n\nAuthors: \nC\u00e9sar Lazzarotto\n\n1\n, Marcelo Fernando Ronsoni\n\n1\n, Leonardo Fayad\n\n1\n, \n\nChristiane Louren\u00e7o Nogueira\n2\n, Maria Luiza Bazzo\n\n2\n, Jana\u00edna Luz \n\nNarciso-Schiavon\n1\n, Leonardo de Lucca Schiavon\n\n1\n, Esther Buzaglo \n\nDantas-Corr\u00eaa\n1 \n\n \n\nAffiliations:  \n1\nDivision of Gastroenterology, Federal University of Santa Catarina \n\n2\nDepartment of Clinical Analysis, Federal University of Santa Catarina \n\n \n\nKey words: C-Reactive Protein, procalcitonin, bacterial infections, \n\nprognosis, liver cirrhosis \n\n \n\nPotential conflict of interest: nothing to report \n\n \n\nAcknowledgments: The authors would like to thank the Laborat\u00f3rio \n\nM\u00e9dico Santa Luzia for the support in the determination in the serum \nprocalcitonin levels. \n\n \n\nABSTRACT \nIntroduction: Bacterial infection is a frequent complication in patients \n\nwith decompensated liver cirrhosis, providing negative impact during \n\nfollow-up of these individuals. Objective: To evaluate the effectiveness \n\nof C-reactive protein (CRP) and procalcitonin (PCT) in diagnosing \n\ninfection and to investigate the relationship between these inflammatory \n\nbiomarkers with mortality after hospital admission. Methods: \n\nProspective study that included consecutive patients with \n\ndecompensated liver cirrhosis who had infection and serum CRP and \n\nPCT investigated at hospital admission. Results: A total of 64 patients \n\nand 81 hospitalizations were analyzed during the study. The mean age \n\nwas 54.31 \u00b1 11.87 years with male predominance (68.8%). Serum \n\nconcentrations of CRP and PCT were significantly higher in infected \n\n\n\n72 \n\n \n\npatients (CRP median: 81.55 vs 6.78, p&lt;0.001, and PCT median: 2.50 \n\nvs 0.19, p&lt;0.001). Areas under ROC curve of CRP and PCT for the \n\ndiagnosis of infection were 0.835 \u00b1 0.052 and 0.86 \u00b1 0.047, \n\nrespectively. Patients who died until the third month after admission had \n\nCRP and PCT medians higher than survivors (PCR 7.04 vs 41.05 p = \n\n0.026, and PCT 0.16 vs 0.94 p = 0.001).  Conclusion: CRP and PCT \n\nwere reliable markers of infection in patients with decompensated liver \n\ncirrhosis. Higher values of CRP and PCT medians were found in \n\npatients who died, although there was no association between infection \n\nat hospital admission and mortality in seven days and three months. \n\nKey words: liver cirrhosis, bacterial infections, acute-phase proteins  \n\nINTRODUCTION \n\nBacterial infections are common in patients with liver cirrhosis, \n\nespecially in the decompensated phase (1). This complication \n\nquadruplicates the mortality risk, with 30% of patients who acquire \n\nbacterial infection dying within a month (2). The higher prevalence of \n\ninfection among patients with advanced degree of liver dysfunction has \n\nas contributing factor the presence of abnormalities in the immune \n\nsystem associated with increased bacterial translocation (3).  \n\nThe diagnosis of infection in patients with chronic liver disease \n\ncauses a significant negative impact during the hospital stay, since it is \n\nresponsible for approximately 30% of deaths in this group of patients \n\n(4).\n \nThe usual clinical and laboratory findings indicative of infection \n\nsuch as fever and leukocytosis may be absent (5). Moreover, the \n\nbacterial cultures require 24-48 hours for providing any results, thus \n\ndelaying diagnosis and treatment (6). Therefore, other clinical and \n\nlaboratory parameters are required for the early identification of \n\ninfection in these patients. \n\nIn recent years, inflammatory biomarkers, such as C-reactive \n\nprotein (CRP) and procalcitonin (PCT) have been investigated as tools \n\nfor quick diagnosis of bacterial infection (7-9). It is known that CRP and \n\nPCT increase rapidly in response to non-specific inflammation produced \n\nmainly by hepatocytes (10-13). Thus, their interpretations could be \n\nmisleading when used in patients with hepatic dysfunction who are \n\nadmitted with infectious pictures (14,15). Nevertheless, some studies \n\nhave shown that CRP and PCT are reliable markers for the differential \n\n\n\n73 \n\n \n\ndiagnosis of bacterial infection in patients with chronic liver disease \n\n(16-18).  \n\nThe high frequency of infection as cause of hospital admission \n\nof patients with decompensated liver cirrhosis justifies the search for \n\nbiomarkers that can provide an early diagnosis, and allow appropriate \n\ntreatment.  Furthermore, there is the possibility of these laboratory tests \n\nalso serving as potential predictive markers of mortality, thus becoming \n\nimportant tools during hospital admission and stay of this population. In \n\nthis context, the purpose of the present study was to evaluate the \n\neffectiveness of CRP and PCT as markers of infection at hospital \n\nadmissions of patients with decompensated liver cirrhosis, and as \n\npredictors of mortality on the seventh day and in the third month after \n\nadmission.   \n\n \n\nMETHODS \n\nPatients \nThis is a prospective study that included all patients admitted to \n\nthe emergency room of a Brazilian tertiary hospital due to acute \n\ncomplications of liver cirrhosis (ascites, hepatic encephalopathy, upper \n\ngastrointestinal bleeding secondary to portal hypertension and \n\nhepatorenal syndrome). We excluded patients with hospitalizations for \n\nelective procedures, admissions related to complications of liver \n\ncirrhosis, doubtful diagnosis of liver cirrhosis, use of antibiotics for a \n\nperiod longer than 12 hours before sampling for laboratory tests and \n\nrefusal or inability of the patient or responsible to understand the terms \n\nof IC. \n\nThe diagnosis of cirrhosis was established either histologically \n\n(when available) or clinically (by combining imaging, clinical and \n\nlaboratory findings, as well as evidence of portal hypertension).  \n\nThe study protocol complies with the ethical principles of the \n\nDeclaration of Helsinki and was approved by the Ethics Committee on \n\nHuman Research of the Federal University of Santa Catarina. \n\n \n\nMethods \n\nPatients were evaluated within 12 hours of admission by one of \n\nthe researchers involved, and the following clinical variables were \n\ncollected: age, gender, race, current alcohol use, illicit drug use, \n\nassociated diseases, prophylactic use of antibiotics, cirrhosis etiology, \n\ncurrent and previous decompensation. All patients underwent laboratory \n\n\n\n74 \n\n \n\nevaluation at admission, and following parameters were considered for \n\nthe study: total leukocytes, neutrophils, sodium, creatinine, albumin, \n\ntotal bilirubin, international normalized ratio (INR), CRP. An aliquot of \n\nthe serum sampled at admission was stored at -20 \u00b0C for PCT \n\nmeasurement, which was performed at the end of data collection. \n\nEvaluation of mortality on the seventh day and in the third month after \n\nadmission was performed by phone call, in case of hospital discharge. \n\nIndividuals with suspected infection at hospital admission were \n\nsubmitted to clinical examination to confirm this diagnosis and to \n\nestablish the primary source of infection. A retrospective analysis of \n\nmedical records was also performed with all patients in the study to \n\nassess the presence of infection.  \n\nThe criteria for the diagnosis of infection followed the \n\ndefinition of the Center for Diseases Control (19).\n \nThe diagnosis of \n\nspontaneous bacterial peritonitis (SBP) was given when neutrophil \n\ncount of the ascitic fluid was ? 250 neutrophils/mm\n3\n, regardless of \n\nnegative culture and in absence of intra-abdominal source of infection \n\n(20). The diagnosis of systemic inflammatory response syndrome \n\n(SIRS) and sepsis was established based on the definition of the \n\nAmerican College of Chest Physicians/Society Of Critical Care \n\nMedicine (ACCP/SCCM) and on diagnostic criteria of the committee of \n\nthe Consensus Conference in 1992 (21). Hepatic encephalopathy was \n\ngraded according to the West Haven criteria (22).\n \nSeverity of liver \n\ndisease was estimated by the Child-Pugh classification system (23) and \n\nMELD (Model for End-Stage Liver Disease) (24) calculated based on \n\nlaboratory tests on admission. \n\n \n\nDetermination of serum CRP and PCT \nCrp and PCT measurements were performed on samples \n\ncollected on hospital admission. Crp serum concentrations were \n\nanalyzed by immunonephelometry with the reagent CardioPhase\n\u00ae\n \n\nhsCRP and a Siemens BNII device (analytical sensitivity of 0.175 \n\nmg/L). Quantitative analysis of PCT was performed by \n\nimunochemiluminescence using Siemens AdviaCentaur XP device and \n\nthe reagent ADVIACentaur BRAHMS PCT (quantitation limits between \n\n0.02 ng/mL and 75 ng/mL). \n\n \n\nStatistical analysis \n\n We performed the Kolmogorov-Smirnov test to evaluate the \n\n\n\n75 \n\n \n\nnormality of variable distribution. Continuous variables were compared \n\nusing Student's t test in the case of normal distribution or Mann-Whitney \n\ntest in the remaining cases. Categorical variables were evaluated by chi-\n\nsquare test. The diagnostic accuracy of acute-phase markers was \n\nanalyzed by ROC curves (receiver operating characteristics) and by \n\ncalculating the sensitivity, specificity, positive and negative predictive \n\nvalues for the cutoff points chosen. Comparisons of the ROC curves \n\nwere performed by MedCalc software version 9.3 (MedCalc Software, \n\nMariakerke, Belgium) using the technique described by Hanley &amp; \n\nMcNeil (25). Values of p smaller than 0.05 were considered statistically \n\nsignificant. All tests were two-tailed and were performed by the SPSS \n\nsoftware, version 17.0 (SPSS, Chicago, IL, USA).  \n\n \n\nRESULTS \n\n \n\nCharacteristics of the sample \n\nWe evaluated all hospital admissions due to decompensated \n\nliver cirrhosis during the period between December 2010 and November \n\n2011. Twenty patients were excluded because sampling for laboratory \n\ntests occurred more than 12 hours after beginning of antibiotic therapy. \n\nThus, from a total of 81 admissions, only 64 patients were eligible for \n\nthe study.  \n\n The mean age of the patients was 54.31 \u00b1 11.87 years, most of \n\nthem were male (68.8%) and Caucasians (87.5%). Current alcohol \n\nconsumption and a history of illicit drug abuse was reported by 46.9% \n\nand 6.5% of the patients, respectively. The main causes of liver cirrhosis \n\nwere hepatitis C and alcohol abuse, reported in 28 (43.8%) and 19 \n\n(29.7%) patients, respectively. Previous episode of decompensated liver \n\ndisease was reported by 37 (59.7%) patients, while two patients (3.1%) \n\nwere on antibiotics prophylaxis (Table 1).  \n\n \n\nFactors Associated with the Presence of Infection on Hospital \n\nAdmission  \n\n Twenty-four patients (29.6%) were reported with infection and \n\nin 13 (54.2%) signs of sepsis were found. The most frequent infections \n\nwere SBP and urinary tract infection, found in 10 (41.7%) and 4 \n\n(16.7%) admissions, respectively (Table 2). Pneumonia and skin \n\ninfection were found in six (25.0%) admissions. Infection was \n\nconfirmed by culture in 14 (58.3%) admissions, and the strains \n\n\n\n76 \n\n \n\nEscherichia coli and Enterococcus sp were found in 72% of these \ncultures. Klebsiela pneumoniae, Staphylococcus sp., Streptococcus sp., \n\nand Morganella morganii were other bacteria responsible for infection \nin this sample. \n\nThe infected patients were compared with the uninfected \n\npatients (Table 3). The median age was similar between the groups. On \n\nthe other hand, patients infected showed significantly higher MELD \n\nscores and a higher rate of individuals classified as C by the Child-Pugh \n\nsystem. As for the clinical signs of decompensated liver cirrhosis, there \n\nwas no difference in the presence of hepatic encephalopathy (p = 0.306) \n\nor upper gastrointestinal bleeding (p = 0.943), while ascites and SIRS \nwere more frequent in infected patients (p = 0.004 and p = 0.019, \n\nrespectively).  \n\nThe median values of total leukocytes and neutrophils were \n\nsignificantly higher in patients with infection (p = 0.049 and p = 0.016, \n\nrespectively), while median serum creatinine and INR (p = 0.003 and p \n= 0.004, respectively). The mean serum albumin levels were lower in \n\ninfected patients (p&lt;0.001), but no difference in serum sodium (p = \n\n0.517) and total bilirubin (p = 0.132) was found between the groups. \n\nThe median serum CRP and PCT levels of the patients included \n\nin the study were 12.3 mg/L (mean 47.02 \u00b1 69.95 mg/L) and 0.35 \n\nng/mL (mean 2.93 \u00b1 7.16), respectively. We observed higher \n\nconcentrations of inflammatory markers of the medians of infected \n\ncirrhotic patients at the time of hospital admission when compared to the \n\nremaining patients (CRP median: 81.55 vs. 6.78 mg/L, p&lt;0.001, and \n\nPCT median: 2.50 vs. 0.19 ng/mL, p&lt;0.001). \n\n \n\nPerformance of CRP and PCT in the Infection Diagnosis on Hospital \n\nAdmission \n\nThe performance of serum CRP and PCT concentrations in the \n\ndiagnosis of infection was assessed by ROC curve (Figure 1). All \n\nhospitalizations were included in the analysis of the PCT accuracy; \n\nhowever, CRP dosages were available in 75 admissions. The areas \n\nunder the ROC curve for CRP and PCT for diagnosing infection were \n\n0.835 \u00b1 0.052 and 0.856 \u00b1 0.047, respectively (p = 0.273). \n Three cutoffs were used for analysis and obtaining diagnostic \n\naccuracy for CRP, according to ROC curve (Table 4). When 5 mg/L \n\nwas set as cutoff in the diagnosis of infection, we found an accuracy of \n\n53% with a sensitivity of 96% and specificity of 36%. Using a cutoff  \n\n\n\n77 \n\n \n\nTable 1. Clinical and epidemiological characteristics of patients \n\nhospitalized with decompensated cirrhosis* \n\nVariables \n\nPatients \n\n(n = 64) \n\nAge (years); mean \u00b1 SD \n\n (median) \n\n54.31 \u00b1 11.87 \n\n(55.0) \nMale, n (%) 44 (68.8) \n\nCaucasian, n (%) 56 (87.5) \n\nCurrent alcohol use\n\u00b6\n n (%) 30 (46.9) \n\nCirrhosis cause, n (%)  \n\nHepatitis C 28 (43.8) \n\nHepatitis B 4 (6.3) \n\nAlcohol 19 (29.7) \n\nAutoimmune hepatitis 1 (1.6) \n\nOther 12 (18.8) \n\nPrevious hepatic decompensation, n (%) 37 (57.8) \n\nDiabetes mellitus, n (%) 16 (25) \n\nHIV infection, n (%) 1 (1.6) \n\nUse of prophylactic antibiotics, n (%) 2 (3.1) \n\nUse of illicit drugs, n (%) 4 (6.25) \n\nSD = standard deviation. HIV = human immunodeficiency virus. * For \n\npatients admitted more than once, we used only the data of the first \n\nhospital admission.  \n\u00b6\nDaily intake of > 20 grams of alcohol in the last \n\nmonth prior to admission.  \n\n \n\nof 10 mg/L showed 69% of accuracy, with sensitivity and specificity of \n\n86% and 62%, respectively. When using a cutoff point of 29.5 mg/L, \n\naccuracy, sensitivity and specificity were 81%, 82%, and 81%, \n\nrespectively.  Similarly, three cutoffs for PCT were used to assess the \n\neffectiveness in diagnosing infection (Table 4). A cutoff of 0.10 ng/mL \n\nhad accuracy of 57%, sensitivity of 96%, and specificity of 40%. When \n\n\n\n78 \n\n \n\nassessing at a level of 0.5 ng/mL, we obtained an accuracy of 78%, \n\nwith sensitivity and specificity of 75% and 79%, respectively. A cutoff \n\nof 1.1 ng/mL showed an accuracy of 83%, sensitivity of 67%, and 90% \n\nof specificity. \n\n With respect to CRP concentrations and Child-Pugh \n\nclassification, the study showed a trend towards higher median CRP in \n\nthose patients classified as C when compared to the combination of \n\nclasses A and B (29.5 mg/L vs. 8.6 mg/L, p = 0.084). On the other hand, \nthe median of PCT concentrations was significantly higher in the Child \n\nC group than in the combined Child A/B group (0.57 ng/mL vs. 0.19 \n\nng/mL, p = 0.002). Median values of CRP and PCT were also correlated \nwith the MELD score. Patients with MELD score&lt;15 showed lower \n\nconcentrations of CRP with a median of 6.6 mg/L, while the group with \n\nMELD score ? 15 had a median of 41.1 (p = 0.002). Similar results were \n\nobserved when comparing the medians of the PCT. The group with \n\nMELD&lt;15 showed a median of 0.17, while a value of 0.89 was found \n\nin the group with MELD ? 15 (p&lt;0.001). \n\n \n\nTable 2. Source of infection observed in patients with decompensated \n\nliver cirrhosis admitted to a hospital emergency unit \n\nInfection source n (%) \n\nSpontaneous bacterial peritonitis  10 (41.7%) \n\nUrinary tract infection  4 (16.7%) \n\nPneumonia 3 (12.5%) \n\nSkin infection 3 (12.5%) \n\nInfection without identified source 2 (8.3%) \n\nGastroenteritis 1 (4.2%) \n\nBacterascites 1 (4.2%) \n\nTotal 24 (100%) \n\n \n\nAssociation between CRP and PCT in early mortality \n\nTo evaluate the mortality of patients admitted more than once, \n\nwe took into account only the last admission. Ten patients (15.6%) \n\ndied by the seventh day after admission. There were no differences in \nthe rate of infected individuals when comparing patients who died with \n\nthose who survived (20.0% vs. 27.3%, p = 1.00). When evaluating \nafter 90 days of admission, 22 subjects (34.9%) died and one patient \n\nwas excluded from the analysis for lack of follow-up. \n\n\n\n79 \n\n \n\nTable 3. Clinical and laboratory variables associated with infection on \n\nadmission \n\nVariables \nAbsence of \n\ninfection \n\n(n = 57) \n\nPresence of \n\ninfection \n\n(n = 24) \n\np \n\nMean age (years) \u00b1 SD  54.58 \u00b1 11.93  54.17 \u00b1 13.28  0.891 \n\nAscites, n (%)  23 (40.4) 18 (75) 0.004 \n\nEncephalopathy, n (%)  31 (54.4) 16 (66.7) 0.306 \n\nUGIB, n(%)\n \n\n28 (49.1) 12 (50.0) 0.943 \n\nChild-Pugh classification, n (%)    0.027 \n\nA 9 (15.8%) 0 (0)  \n\nB 28 (49.1) 9 (37.5)  \n\nC 20 (35.1) 15 (62.5) 0,023 \n\nMELD, mean \u00b1 SD  14.74 \u00b1 5.99  20.29 \u00b1 6.25 &lt;0.001 \n\nSIRS, n (%) 15 (28.6) 13 (54.2) 0.019 \n\nTax > 38.0 \no\nC or &lt;36.0 \n\no\nC, n \n\n(%) \n\n11(19.6) 4 (16.7) 1.00 \n\nTotal leukocytes (mm\n3\n), median 7.035 10.040 0.049 \n\nNeutrophils (mm\n3\n), median 4.343 8.112 0.016 \n\nSodium (mEq/L), mean \u00b1 SD 134.64 \u00b1 4.81 133.87 \u00b1 4.77 0.517 \n\nCreatinine (mg/dL), median 1.00 1.70 0.003 \n\nINR, median 1.38 1.53 0.004 \n\nAlbumin (g/dL), mean \u00b1 SD 2.54 \u00b1 0.64 1.87 \u00b1 0.39 &lt;0.001 \n\nTotal bilirubin (mg/dL), median 1.66 2.80 0.132 \n\nCRP (mg/l),median 6.78 81.55 &lt;0.001 \n\nPCT (ng/ml) median 0.19 2.50 &lt;0.001 \n\nSD = standard deviation. UGIB = upper gastrointestinal bleeding. MELD = \n\nModel for End-Stage Liver Disease. SIRS = systemic inflammatory response \n\nsyndrome. INR = international normalized ratio. CRP = C-reactive protein. \n\nPCT = procalcitonin. Tax = axillary temperature \n\n\n\n80 \n\n \n\n \n\nThe rate of infections among those who died during the 90-day \n\nafter hospital admission follow-up was numerically higher when \n\ncompared to those who survived; however, no statistical difference \n\n(36.4% vs. 19.0%, p = 0.129) was reported. \n\nThe measurements of CRP and PCT were also correlated with \n\ndeath on the seventh day and in the third month after admission. There \n\nwas no difference between the median CRP and death on the seventh \n\nday (p = 0.531). However, we noticed a significant difference in median \n\nvalue of PCT when correlated with death in seven days (0.22 vs. 0.94, p \n\n= 0.009). When comparing the medians of CRP and PCT to death in \n\nthree months after admission, we found a statistically significant \n\ndifference for both markers (CRP 7.04 vs. 41.05, p = 0.026; and PCT \n\n0.16 vs. 0.94, p = 0.001). \n\n \n\nFigure 1. ROC curves of C-reactive protein (CRP) and procalcitonin \n\n(PCT) for the diagnosis of infection at admission. The area under the \n\ncurve represents the power of the tests. \n\n\n\n81 \n\n \n\nTable 4. Effectiveness of cutoff points of C-reactive protein and \n\nprocalcitonin in diagnosing infection at hospital admission \n\n \nPontos de \n\ncorte \n\nAcur\u00e1cia \n\n(%) \n\nS \n\n(%) \n\nE \n\n(%) \n\nVPP \n\n (%) \n\nVPN  \n\n(%) \n\n           \n0,10 57 96 40 40 96 \n\nPCT 0,50 78 75 79 60 88 \n\n 1,10 83 67 90 73 86 \n\n \n\n \n5,0 53 96 36 38 95 \n\nPCR 10.0 69 86 62 49 92 \n\n 29,6 81 82 81 64 92 \n\nPCT = Procalcitonin (ng/ml). CRP = C-reactive protein (mg/L). PPV = \n\npositive predictive value. NPV = negative predictive value. \n\n \n\n \n\nTable 5. Relationship of C-reactive protein and procalcitonin with death \n\non the seventh day and in the third month after admission \n\n Death 7\nth\n\n day (n:10)   \n\n No Yes p \n\nCRP, mg/L (median) 9.0 33.15 0.531 \n\nPCT, ng/ml (median) 0.22 0.94 0.009 \n\n Death 3 months* (n:22)   \n\n No Yes p \n\nCRP, mg/L (median) 7.04 41.05 0.026 \nPCT, ng/ml (median) 0.16 0.94 0.001 \n\nCRP = C-reactive protein. PCT = procalcitonin. * Lost contact with one \n\npatient during 3-month follow-up.  \n\n \n\n\n\n82 \n\n \n\nDISCUSSION \n\n The diagnosis of liver cirrhosis represents a significant adverse \n\nimpact, increasing the risk of sepsis, acute respiratory failure, and death \n\nduring hospitalization (26). Thus, early diagnosis and treatment are \n\nessential to provide a more favorable prognosis for these individuals \n\n(27).  \n\n Previous clinical studies involving a variable number of patients \n\nfound conflicting results regarding the analysis of CRP as a marker of \n\ninfection in patients with liver cirrhosis (16-18, 28,29). The accuracy for \n\nthe diagnosis of infection as measured by the area under the ROC curve \n\nranged from 0.641 to 0.93 (16-18,28,29). An interesting fact observed in \n\nthese studies was the difference in the cutoffs used to identify infection, \n\nwith values raging between 9.2 mg/L and 80 mg/L. This significant \n\nvariation in cutoff can be explained by differences in the severity of \n\ninfection episodes among studies, as well as in the small number of \n\nindividuals studied. A cross-sectional study that evaluated 98 patients \n\nwith liver cirrhosis admitted to an emergency unit suggested that a \n\ncutoff of 24.7 mg/dL is the best value for diagnosing bacteremia and \n\nsepsis in this population (16). This cutoff showed an accuracy for \n\ndiagnosing sepsis of 81% when evaluated using the ROC curve. In this \n\nstudy, 29.5 mg/L was the best cutoff evaluated with the ROC curve. \n\nPapp and colleagues prospectively evaluated 368 patients with liver \n\ncirrhosis admitted to a hospital unit (17). These authors observed that a \n\nCRP value of 9.2 mg/L is the best cutoff for diagnosing infection with \n\nan accuracy of 93%. One must consider that 25% of patients in this \n\nstudy had mild infections, mainly in the urinary tract (17). In our study, \n\nwe noticed a considerable decrease in accuracy and specificity when \n\nusing a CRP cutoff of 10 mg/L. One factor that may have influenced the \n\npoorer diagnostic accuracy at this cutoff value was the presence of \n\nserious infections, since more than half of cirrhotic patients admitted \n\nwith sepsis showed signs of infection. \n\n  PCT has a favorable pharmacokinetic property. The rapid peak \n\nof plasma levels (at around 6 hours) after endotoxemia (30) favors early \n\ndiagnosis of bacterial infection, helping with the diagnostic approach \n\nand an adequate treatment of patients with decompensated chronic liver \n\ndisease. Bota and colleagues prospectively evaluated 864 patients \n\nhospitalized in an intensive care unit and of this total, 79 individuals \n\nwere suffering from liver cirrhosis (29). No difference was found \n\n\n\n83 \n\n \n\nbetween the concentrations of CRP and PCT in patients with or without \n\nliver cirrhosis, suggesting that although the liver is considered the main \n\nproducer of these inflammatory biomarkers, serum concentrations are \n\nnot suppressed in patients with chronic liver failure (29) .  \n\nIn this study, the area under the ROC curve for the PCT in the \n\ndiagnosis of infection was 0.856. There are few studies evaluating the \n\ndiagnostic accuracy of PCT in patients with chronic liver disease, but \n\nthe results reported were favorable (16,17,28,29,31-33). In these studies, \n\nthe area under the ROC curve ranged between 0.68 and 0.98, which is in \n\nagreement with the findings of this study. In this study, the cutoff that \n\nshowed the best overall performance was 1.10 ng/mL, with an accuracy \n\nof 83%, sensitivity of 67%, and 90% of specificity. Connert and \n\ncolleagues prospectively evaluated 127 patients with liver cirrhosis with \n\nor without decompensation (31). The cutoff of 0.58 ng/mL was \n\nconsidered the best value for the differential diagnosis of infection in \n\ndecompensated patients (31). In the study of Elefsiniotis and colleagues, \n\nPCT was measured in 106 patients hospitalized with acute or chronic \n\nliver disease, and the cutoff of 0.5 ng/mL showed the best accuracy in \n\nthe diagnosis of bacterial infection (32). However, 46% of non-infected \n\npatients with alcoholic hepatitis and superimposed cirrhosis, as well as \n\n30% of non-infected patients with acute viral hepatitis, especially those \n\nwith significant cirrhosis or fibrosis, showed slight higher PCT. The \n\nauthors concluded that a cutoff value >0.5 ng/mL is required for the \n\ndifferential diagnosis of infection in these groups of patients with liver \n\ndisease (32). Thus, as discussed above for the PCR, it is likely that \n\nhigher cutoffs show better performance in patients admitted to \n\nemergency units, who often present with more serious infections and \n\nother medical conditions, which can lead to increased serum levels of \n\nacute phase markers. \n\n Despite the numerical difference, no statistically significant \n\ndifference in mortality on the seventh day and in the third month after \n\nhospital admission was found between infected and non-infected \n\ncirrhotic patients. Previous studies have shown that infection causes a \n\nconsiderable deterioration in the prognosis of patients with chronic liver \n\ndisease (34). It is likely that the findings of this study are justified by the \n\nrelatively small sample size. \n\n  In this study, higher levels of CRP and PCT on admission were \n\nassociated with mortality in three months. These findings are similar to \n\nthose reported by Cervoni and colleagues, who demonstrated that in \n\n\n\n84 \n\n \n\npatients with advanced liver cirrhosis, CRP levels ? 29 mg/L were \n\nindependent predictors of mortality in six months (35). Moreover, in a \n\nstudy involving 368 patients with liver cirrhosis (17), higher levels of \n\nCRP were also good predictors of infection in three months.  However, \n\na retrospective study of 202 cirrhotic patients evaluated CRP serum \n\nconcentrations at admission and a relationship with mortality in 30 days \n\nwas not observed; however, the quantitative decrease in concentrations \n\nat four or five days after admission was found to be associated with \n\nbetter survival rate of these patients (36). Contradicting results were also \n\nfound in studies evaluating the relationship between PCT levels and \n\nmortality. Connert and colleagues demonstrated an association between \n\nPCT concentrations >0.58 ng/mL (p&lt;0.001) and mortality at two \n\nmonths follow-up (31). However, this relationship was not observed by \n\nCervoni and colleagues in a study that followed 148 cirrhotic patients \n\nwith Child-Pugh score ? B8 for a longer period (up to six months) (35). \n\nIt is likely that the disparate results observed in the mentioned studies \n\nreflect the different clinical scenarios evaluated and specific \n\ncharacteristics of the study designs. \n\n Some limitations of this study should be addressed. The \n\nrelatively small number of patients and the inclusion of individuals who \n\nwere readmitted to the hospital due to hepatic decompensation after \n\nhaving been discharged may allow the occurrence of selection bias, \n\nimpairing the analysis of results. However, the number of patients \n\nincluded in most studies evaluating inflammatory markers for the \n\ndiagnosis of infection in patients with hepatic cirrhosis was similar to \n\nour sample. However, the results presented herein require external \n\nvalidation by prospective studies with a greater number of patients, \n\nespecially with regard to the acute-phase cutoff markers. Another \n\nlimitation is the fact that our study was conducted in an emergency \n\nroom without standardized infection diagnosis at the time of admission, \n\nwhich may have provided a misleading categorization of the study \n\nsubjects. However, the prospective nature of this study, with follow-up \n\nof all patients included at hospital admission and analysis of medical \n\nrecords, makes such a bias unlikely. \n\n In conclusion, CRP and PCT showed good accuracy in \n\ndiagnosing bacterial infection in cirrhotic patients admitted due to \n\ncomplications of the disease. Cutoffs higher than those previously \n\nsuggested in the literature may be required, especially in the context of \n\npatients admitted to emergency rooms in whom the most serious \n\n\n\n85 \n\n \n\ninfections and other medical complications might be associated with \n\nsignificantly increased levels of acute-phase markers. The association \n\nbetween higher CRP and PCT levels and short-term mortality suggest \n\nthat these biomarkers have a potential as prognostic predictors in \n\npatients with liver cirrhosis. \n\nREFERENCES \n\n1.  Fern\u00e1ndes J, Navasa M, G\u00f3mez J, Colmenero J, Vila J, Arroyo V et \nal. Bacterial infections in cirrhosis: epidemiological changes with \n\ninvasive procedures and norfloxacin prophylaxis. Hepatology 2002; \n\n35:140-48. \n\n2. Arvaniti V, D`Amico G , Fede G, Manousou P, Tsochatzis E, \nPleguezuelo M et al. Infections in patients with cirrhosis increase \n\nmortality four-fold and should be used in determining prognosis. \n\nGastroenterology 2010;139:1246-56. \n\n3. Garcia-Tsao G. Gut microflora in the pathogenesis of the \ncomplications of cirrhosis. Best Pract Res Clin Gastroenterol \n\n2004;18(2):353-72.  \n\n4. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and \nmultiorgan failure in cirrhosis. Semin Liver Dis 2008;28(1):26-42. \n\n5. Wyke RJ. Problems of bacterial infection in patients with liver \ndisease. Gut 1987;28:623-41. \n\n6. Jin M, Khan  AI. Procalcitonin: uses in the clinical laboratory for \nthe diagnosis of sepsis. Lab Med 2010;41(3):173-77.  \n\n7. Liu K T, Lin TJ, Chan HM. Characteristics of febrile patients with \nnormal white blood cell counts and high C-reative protein levels in \n\nan emergency department. Kaohsiung J Med Sci 2008;24:248-53. \n\n8. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In \ncritically ill patients, serum procalcitonin is more useful in \n\ndifferentiating between sepsis and SIRS than CRP, Il-6, or LBP. \n\nCrit Care Res Pract 2011;2011:1-6. \n\n9. Pourakbari B, Mamishi S, Zafari J, KhairkhanH, Ashtiani MH, \nAbedini M et al. Evaluation of procalcitonin and neopterin level in \n\nserum of patients with acute bacterial infection. Braz J Infect Dis \n\n2010;14(3):252-5. \n\n10.   Lipman J, Ho KM. An update on C-reactive protein for \nintensivists. Anaesth Intensive Care 2009; 37: 234-41. \n\n\n\n86 \n\n \n\n11.   Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site \nof C-reactive protein formation. J Exp Med 1966;123:365-78. \n\n12.   Kretzschmar M, Kruger A, Schirrmeister W. Procalcitonin \nfollowing elective partial liver resection \u2013 origin from the liver?. \n\nActa Anaesthesiol Scand 2001; 45: 1162\u20137. \n\n13.   Meisner M, Muller V, Khakpour Z, Toegel E, Redl H. Induction of \nprocalcitonina and proinflamatory cytokines in an anhepatic baboon \n\nendotoxin shock model. Shock 2003; 19(2):187-90. \n\n14.   Le Moine O, Devi\u00e8re J, Devaster JM, Crusiaux A, Durand F, \nBernuau J et al. Interleukin-6: an early marker of bacterial infection \n\nin decompensated cirrhosis. J Hepatol 1994;20:819-24. \n\n15.   Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS et al. \nProduction of C-reactive protein in Escherichia coli-infected \n\npatients with liver dysfunction due to liver cirrhosis. Diagn \n\nMicrobiol Infect Dis 2005;51:227-30.  \n\n16.   Li CH, Yang RB, Pang JHS. Procalcitonin as a biomarker for \nbacterial infections in patients with liver cirrhosis in the emergency \n\ndepartment. Acad Emerg Med 2011;18:122-6. \n\n17.   Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J et \nal. Acute phase proteins in the diagnosis and prediction of cirrhosis \n\nassociated bacterial infections. Liver Int 2012;32(4):603-611. \n\n18.  Tsiakalos A, Karatzaferis A, Ziakas P, Hatzis G. Acute-phase \nproteins as indicators of bacterial infection in patients with cirrhosis. \n\nLiver Int 2009;29(10):1538-42. \n\n19.  Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC \ndefinitions for nosocomial infectious. Am J Infect Control \n\n1988;16:128-40.  \n\n20.  Runyon B A. Management of adult patients with ascites due to \ncirrhosis : an update. Hepatology 2004;49(6):2087-107.  \n\n21.   Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus \nWA, et al. Definitions for sepsis and organ failure and guidelines \n\nfor the use of innovative therapies in sepsis. The ACCP/SCCM \n\nConsensus Conference Committee. American College of Chest \n\nPhysicians/Society of Critical Care Medicine. Chest \n\n1992;101:1644-55. \n\n22.   Bajaj JA. Review article: the modern management of hepatic \nencephalopathy. Aliment Pharmacol Ther 2010;31:537-47. \n\n23.   Angermayr B, Cejna M, Karnel F, Gschwantler  M, Koenig F, \nPidlichJ et al. Child-Pugh versus MELD score in predicting survival \n\n\n\n87 \n\n \n\nin patients undergoing transjugular intrahepatic portosystemic \n\nshunt. Gut 2003(52):879-85.   \n\n24.   Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau \nTM, Kosberg CL et al. A Model to predict survival in patients with \n\nend-stage liver disease. Hepatology 2001;33:464-70.  \n\n25.   Hanley JA, McNeil BJ. A method of comparing the areas under \nreceiver operating characteristic curves derived from the same \n\ncases. Radiology 1983;148:839-43. \n\n26.   Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for \nsepsis and death. Chest 2003;114:1016-20. \n\n27. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-\nTsao G et al. Sepsis in cirrhosis: report on the 7\n\nth\n meeting of the \n\ninternational ascites club. Gut 2005;54:718-25.   \n\n28.  Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Aubert G et al. \nSerum and ascitis procalcitonina levels in cirrhotic patients with \n\nspontaneous bacterial peritonitis:diagnostic value and relationship to \n\npro-inflamatory cytokines. Intensive Care Med 2000;26:1082-8. \n\n29.  Bota DP, Van Nuffelen M, Zakariah AN, Vincebt JL et al. Serum \nlevels of C-reactive protein and procalcitonin in critically ill patients \n\nwith cirrhosis of the liver. J Lab Clin Med 2005;146:347-51. \n\n30.  Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. \nProcalcitonin increase after endotoxin injection in normal subjects. J \n\nClin Endocrinol Metab 1994;79:1605-8.  \n\n31.  Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker \nof infection in decompensated cirrhosis. Z Gastroenterol \n\n2003;41:165-70. \n\n32.  Elefsiniotis I S, Skounakis M, Vezali E, Pantazis KD, Petrocheilou \nA, Pirounaki M, et al. Clinical significance of serum procalcitonin \n\nlevels in patients with acute or chronic liver disease. Eur J \n\nGastroenterol Hepatol 2006;18:525-30. \n\n33.  Schepis F, Bianchini M, Ferretti I, Marino M, Bonfreschi S, \nDattomo G et al. Procalcitonin is the best diagnostic and prognostic \n\nmarker of sepsis in decompensated cirrhotic patients. J Hepatol \n\n2010;52:S59-182. \n\n34.   Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F \net al. Bacterial infection in patients with advanced cirrhosis: a \n\nmulticentre prospective study. Dig Liver Dis 2001;33:41-8.      \n\n35.   Cervoni JP, Th\u00e9venot T, Weil D, Muel E, Barbot O, Sheppard F, \nMonnet E, Di Martino V. C-reactive protein predicts short-term \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Borzio%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Salerno%20F%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Piantoni%20L%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Cazzaniga%20M%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Angeli%20P%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Bissoli%20F%22%5BAuthor%5D\n\n\n88 \n\n \n\nmortality in patients with cirrhosis. J Hepatol. 2012 Jun;56(6):1299-\n\n304. \n\n36. Ha YE, Kang CI, Joo EJ, Joung MK, Chung DR, Peck KR et al. \nUsefulness of C-reactive protein for evaluating clinical outcomes in \n\ncirrhotic patients with bacteremia. Korean J Intern Med 2011;26(2):195-\n\n200. \n\n \n\n \n\n \n\n \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Ha%20YE%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Kang%20CI%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Joo%20EJ%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Joung%20MK%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Chung%20DR%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Peck%20KR%22%5BAuthor%5D"}]}}}